



MEASURING TREATMENT PREFERENCES OF PEOPLE WITH 





Ellen M. Janssen 
 
 
A dissertation submitted to Johns Hopkins University in conformity with the requirements for the 








© 2017 Ellen Janssen 




Stated-preference methods are increasingly used to obtain patient-preference information for use 
in healthcare decision making. However, there remains a paucity of literature transparently 
reporting on the application of good research principles through all phases of stated-preference 
study design.  
In part one of this dissertation, we applied a novel 5-step framework to the development of a 
stated-preference instrument that could measure the treatment preferences of people with type 2 
diabetes. The developed choice experiment contained 6 attributes (A1c decrease, blood glucose 
stability, low blood glucose, nausea, additional medicine, and cost). 
In part two of this dissertation, we applied good research practices to the implementation of the 
developed discrete-choice experiment. Members of a United States online panel with type 2 
diabetes completed a web-enabled, self-administered survey that elicited choices between 
treatment profile pairs. 552 participants (51% male) completed the survey. We found that patients 
with type 2 diabetes value both the benefits of their treatment, and the harms and treatment 
burden associated with treatment.  
In part three of this dissertation, we sought to assess the impact of educational attainment on 
treatment preferences of patients with type 2 diabetes.  231 participants had completed high 
school or less, 156 participants had completed some college, and 165 participants had a college 
degree or more education. Participants with college or more were willing to pay more for A1C 
decreases than participants who had completed some college or high school or less.  
In part four of this dissertation, we conduct a targeted literature review to identify tests for 
assessing validity and reliability of a DCE. We identified four domains for the validity of a DCE: 
measurement validity, preference reliability, decision processes, and choice rationality. These 
 iii 
domains consist of 14 components that can be identified using 24 possible tests of validity and 
reliability.  
Using treatment preferences for type 2 diabetes as a case study, we demonstrated good research 
practices for the design, implementation, analysis, and evaluation of a stated-preference study.  
The applications of our approach will help other researchers conduct high quality stated-
preference research for use in healthcare decision making processes.  
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CHAPTER ONE  
-  




Diabetes is a set of metabolic diseases that results from defects in insulin action and/or secretion. 
It characterized by chronic hyperglycemia and results in disturbances of carbohydrate, fat, and 
protein metabolism.
 1
 Given the World Health Organization’s (WHO) criteria, diabetes mellitus is 
diagnosed by fasting plasma glucose level ≥126 mg/dL (7.0 mmol/L), 2-hour plasma glucose 
level ≥200 mg/dL (11.1 mmol/L) after a 75-g oral glucose load,
 2 
or a glycated hemoglobin level 
of ≥6.5%.
 3 
Impaired glucose tolerance, impaired fasting glucose, and glycated hemoglobin values 
between 5.7% and 6.4% are collectively associated with increased risk of diabetes development 
and are often known as prediabetes.
 4
 Diabetes is associated with long-term micro-vascular and 
macro-vascular complications that result in damage and sometimes failure of various organs, 





Traditionally diabetes mellitus has been classified into two primary types: autoimmune (type 1) 
and nonautoimmune (type 2). With an increased, though still limited, understanding of its 
etiology the classification of diabetes mellitus has advanced.
 1
 Type 1 diabetes mellitus was 
originally classified as juvenile diabetes and then as insulin dependent diabetes. Now differences 
in antibody positive (type 1a) and antibody negative (type 1b) are recognized.
 6
 Slower adult-
onset forms of autoimmune related diabetes are now recognized separately from type 2 diabetes 
as latent autoimmune diabetes of adults [LADA] and may include distinctions for more subtle 
forms of immune involvement.
 7
 I simplify the discussion and merely consider type 1 and type 2 
diabetes. Since this study is interested in the patient experience of living with diabetes, 
particularly type 2 diabetes, and most people are still diagnosed with type 1 or type 2 diabetes, 
these two classifications are appropriate. 
 3 
Type 1 diabetes is an autoimmune disorder in which the body’s immune system attacks the β-
cells in the pancreas, the cells that produce insulin, which eventually eliminates the production of 
insulin. Type 1 diabetes is associated with a genetic predisposition: monozygotic twins have a 
50% concordance rate and dizygotic twins have a concordance rate of 10%.
 8,9
 Onset of type 1 
diabetes symptoms occurs because of a combination of β -cell loss and dysfunction. Despite 
extensive research, the timeframe and nature of the autoimmune abnormalities and destruction of 
the β-cells is still unclear.
 1
 
Type 2 diabetes is characterized by insulin resistance and insulin deficiency. Just like type 1 
diabetes, type 2 diabetes is associated with a genetic predisposition and multiple genetic 
mutations have been identified.
 10
 However, for diagnosis and treatment of type 2 diabetes, the 
focus is generally on environmental factors since it is often not possible to identify genetic 
abnormalities. In type 2 diabetes, chronic glucotoxicity and lipotoxicity have been associated with 
diminishing insulin secretion by decreasing the amount of insulin secretory granules in the 
pancreas or by decreasing the conversion of proinsulin to insulin.
 1
 In persons with type 2 
diabetes, β-cell function deteriorates with increasing hyperglycemia despite treatment.
 11
 In 
autopsy studies, individuals with type 2 diabetes showed a reduced β -cell mass.
 12
  
Type 2 diabetes is often associated with obesity and the metabolic syndrome, but 15% of whites 
and the majority of south Asians with type 2 diabetes are non- obese.
 13,14
 Many individuals with 
obesity have insulin resistance and progress to diabetes, but some never develop overt diabetes; 
their β-cells continue to function, and they are able to regulate their glycemic levels by 
compensating for increased insulin resistance with increased insulin secretion.
 1
 The heterogeneity 





Treatment of diabetes 
Diabetes treatment most often requires a combination of lifestyle adaptation and medication. The 
ADA and EASD recommend a patient-centered approach that incorporates patient preferences, 
cost and side effects of medications, effects on body weight, and risk of hypoglycemia. Lowering 
A1c levels below or around 7% has been shown to reduce macrovascular and microvascular 
complications of diabetes. Therefore, the recommended A1c goal for many nonpregnant, non-
elderly adults is <7%.
 16
 
Lifestyle interventions that include nutrition therapy and exercise are important in the 
management of diabetes.
 17,18
 Weight loss may be clinically beneficial for people with type 2 
diabetes, especially when undertaken in early stages of the disease.
 19
 Diabetes education 
programs that included nutrition therapy, both at an individual and at a group level, have reported 
A1c decreases of 0.5–2% for type 2 diabetes.
 20-22
 The ADA and the American College of Sports 
Medicine summarize the evidence for the benefits of exercise in people with type 2 diabetes.
 23
 
Exercise interventions have been shown to lower A1c by about 0.66% in people with type 2 
diabetes, even when no significant weight loss occurred.
 24
 Higher levels of exercise intensity are 
associated with a greater improvement in A1c levels and fitness,
 25
 and a slowing decline in 
mobility among overweight patients with diabetes.
 26
  
While diet and exercise are advocated in the management of diabetes, there is no evidence of the 
benefit of comprehensive lifestyle interventions alone on patient-oriented outcomes, all-cause 
mortality, cardiovascular, and microvascular outcomes.
 27
 There exist multiple types of glucose 
lowering medication: eight classes of oral medications, a class of subcutaneous medications, and 
insulin.
 28-31
 These treatments are associated with a range of side effects, including weight and 




A majority of diabetes patients use only an oral medication, and about 14% of diabetes patients 
use neither insulin nor an oral medication
 32
 (Table 1-1). 
Table 1-1 Treatment for type 2 diabetes among people age 18 and older, United States 
 
Treatment guidelines emphasize the need to incorporate patient preferences in achieving 
treatment goals.
 33-35
 However, estimated rates of non-adherence for oral diabetes medications are 
high at 35.1%.
 36
 In addition, many people with type 2 diabetes are non-adherent to their other 
medications such as statins (non-adherence at 41.8%).
 36
 Younger patients (<65 years), patients 
new to therapy or on twice-daily doses, women, black or Hispanic patients, and patients with high 
Charlson Comorbidity index scores are more likely to be non-adherent.
 37,38
 Higher out-of-pocket 
expenses are also associated with non-adherence
 38




Metformin is considered the first line treatment for type 2 diabetes (if not contraindicated).
 39
 
Metformin is generally considered safe and effective, is inexpensive, and may reduce risk of 
cardiovascular events.
 40
 About 20-30% of people that take metformin experience severe 
gastrointestinal side effects.
 41
 In most people these side effects are temporary but less than 5% of 
people need to stop taking metformin because continuous side effects.
 41
 When metformin does 
not result in appropriate glycemic control, another medication should be added. Overall, each new 
 Number of adults (millions) Percentage (unadjusted) 
Insulin only 2.9 14.0 
Both insulin and oral medication 3.1 14.7 
Oral medication only 11.9 56.9 
Neither insulin nor oral medication 3.0 14.4 
Source: National Center for Chronic Disease Prevention and Health Promotion. National Diabetes 
Statistics Report, 2014. Centers for Disease Control and Prevention. 2014 
 6 
class of noninsulin medications added to the treatment regimens lowers A1c with approximately 
0.9–1.1%.
 28
 Many patients with type 2 diabetes eventually require the use of insulin.
 39
  
Diabetes as a public health problem 
Diabetes is a chronic disease that poses a significant public health burden in the US and around 
the globe. Diabetes affects 29.1 million people (9.3%) in the US.
 32
 Diabetes incidence has 
increased by 50% over the past decade.
 42
 In 2012, 1.7 million people 20 years or older (or 7.8 per 
1000 people) in the US were newly diagnosed with diabetes.
 32
 Approximately 90-95% of adults 
with diabetes suffer from type 2 diabetes.
 32
 The number of people more than 65 years of age with 
diabetes is projected to increase by 4.5-fold between 2005 and 2050.
 43,44
 In the entire US 
population the number of people with diagnosed and undiagnosed diabetes will increase from 
23.7 million to 44.1 million from 2009-2034.
 45
  
Diabetes is associated with a number of microvascular and macrovascular complications. 
Microvascular complications include eye disease (retinopathy), kidney disease (nephropathy), 
and neural damage (neuropathy).
 46
 Macrovascular complications include cardiovascular disease 
such as myocardial infarction and cerebrovascular disease such as strokes. Acute metabolic 
complications associated with mortality include diabetic ketoacidosis from chronic 
hyperglycemia and coma from hypoglycemia.
 46





 and sexual dysfunction.
 49
  
Complications of diabetes result in significant morbidity and costs
 50
 and are associated with a 
reduced quality of life compared to the general population.
 51
 Diabetic nephropathy represents the 
major cause of end-stage renal failure in Western societies.
 52
 Diabetic retinopathy is the leading 
cause of blindness among adults aged 20–74 years,
 53,54
 and most people with diabetes,
 55
 exhibit 




 and some populations with diabetes exhibit a lifetime risk of lower 
extremity amputation of 15%.  People with diabetes have a risk of myocardial infarction 
equivalent to that of non-diabetic individuals with a history of myocardial infarction.
 57
 This 
equates to a threefold increased risk compared with the general population.
 58
 Cardiovascular 
disease accounts for more than half of the mortality seen in the diabetic population
 57,59
 and 
diabetes is the sixth leading cause of death in the US.
 32
 
Diabetes disproportionately affects vulnerable populations such as minorities
 32
 and the elderly
 60
 
(Figure 1-1). Compared to non-Hispanic whites, minority populations suffer a higher prevalence 
and 50-100% greater burden of illness and mortality from diabetes.
 61
 While ethnic minorities 
spend less on diabetes healthcare than whites, this difference seems to be mainly based on 
differences in access to care between whites and blacks or Hispanics.
 62,63  




In addition, prevalence of diabetes increases significantly with age.
 32
 Because many older people 
meet ADA criteria for pre-diabetes, less than 30% of the US population older than 65 years of age 
have normal glucose levels
2 
than 25% of adults over 65 years old in the United States have 
diagnosed or undiagnosed diabetes,
 32
 and approximately 40% of people with a known diagnosis 




Economic Burden of Diabetes 
Diabetes, including diagnosed and undiagnosed diabetes, pre-diabetes, gestational diabetes 
mellitus (GDM) and complications resulting from diabetes, accounts for a significant economic 
burden. Total estimated cost of diagnosed diabetes in 2012 was $245 billion, which includes $176 
billion in direct medical costs and $69 billion in reduced productivity.
 64
 This presents a 41% 
increase from previous estimates of total costs of diabetes in 2007. The largest components of 
direct costs are hospital inpatient care (43%), medications to treat diabetes complications (18%), 
diabetes medications and supplies (12%), physician office visits (9%), and nursing/residential 
facility stays (8%).  
The average annual medical cost per case of undiagnosed diabetes is $2,864, and for pre-diabetes 
is $443.
 65
 People with diagnosed diabetes incur average medical expenditures of about $13,700 
per year, of which about $7,900-9,677
 64,65
 is attributed to diabetes. People with 
diagnosed diabetes, on average, have medical expenditures approximately 2.3 times higher than 
what expenditures would be in the absence of diabetes. Better A1c control and complications are 
associated with between $67-$158 lower cost of diabetes treatment.
 66
  
Generally, direct costs of diabetes treatment are higher than indirect costs of diabetes.
 67
 Overall, 
people with diabetes are less likely to be employed
 67
 and more likely to have work limitations.
 68
 
Workplace productivity effects range from no impact of diabetes on lost workdays
 69,70









 a person a year. Total indirect costs of diabetes include costs because of 
absenteeism ($5 billion), decreased productivity at work for the employed ($20.8 billion), and 
decreased productivity for people not in the labor force ($2.7 billion). In addition, indirect costs 




Compared to other countries, the USA has high direct and indirect cost of diabetes, even after 
controlling for GDP per capita.
 67
 Care for people with diagnosed diabetes accounts for more than 
1 in 5 healthcare dollars in the US. 62.4% of the cost for diabetes care in the US is provided by 
government insurance (including Medicare, Medicaid, and the military), 34.4% is paid for by 
private insurance, and 3.2% is paid for by the uninsured.
 64
  
Annual diabetes-related spending in the US is expected to increase from $113 billion to $336 
billion between 2009-2034.
 45
 The Medicare eligible diabetes population is expected to rise from 
8.2 million in 2009 to 14.6 million in 2034 with an associated increase of Medicare spending on 
diabetes from $45 billion to $171 billion. In addition, costs of diabetes, as well as its adverse 
labor market effects, increase over time
 73
 and with disease severity,
 74
 indicating that early 
investments into prevention and disease management may be able to reduce costs.
 67
  
Patient preferences  
Preferences and Diabetes 
Due to chronic nature of the disease and the large range of treatment options and health 
outcomes, treatment preferences for diabetes are particularly sensitive and complex.
 75,76
 While 
treatment options for type 2 diabetes have expanded, poor adherence to effective interventions 




little is actually known about patient preferences for treatment.
 28,76
 Certain experts acknowledge 
the importance of patient preferences
 77
 and the American Diabetes Association and the European 
Association for the Study of Diabetes recommend a patient-centered approach that incorporate 
the patient’s individual needs, values and preferences.
 77
 Despite these viewpoints, various 
treatment guidelines on type 2 diabetes do not address balancing the relative priorities of different 
treatment goals, and do not explicitly incorporate patient preferences.  
Several literature reviews of patient preferences in type 2 diabetes have been conducted.
 76,78,79
 
Identified studies that investigated trade-offs considered a wide range of attributes, including 
measures of blood glucose control, hypoglycemia, weight gain, gastrointestinal side effects, heart 
attack risk, water retention, treatment protocol, method of administration, costs, and need for self-
monitoring or laboratory testing.
 76
 Preferences towards drug administration were associated with 
previous experience with injectable diabetes medicine. However, Von Arx et al concluded that 
drug administration did not appear to be a strong driver of preferences.
 79
  
Willingness to pay (WTP) estimates for glucose lowering medication or for avoidance of 
hypoglycemic events varied widely across studies.
 79
 For example, patients were willing to accept 
a higher risk for fewer restrictions on diet.
 80
 In addition, the importance of drug administration or 
weight changes has not been well established. Uncertainty persists firstly because few studies are 
of high quality.
 78
 Second, subgroup analyses were limited, potentially because of sample size 
restrictions.
 78
 Third most studies identified were industry funded;
 76,78,79
 studies funded through 
other venues could significantly add to the existing literature.  
Despite the growing literature exploring the treatment preferences of patients with type 2 
diabetes,
 76,78,79
 many applications inadequately engage patients and other stakeholders in the 
development of these instruments and uncertainty regarding patient-preference in type 2 diabetes 
still exists.
 76,78,79
 By facilitating patient-centered decision making in type 2 diabetes, 
 11 
improvements in adherence, satisfaction, and quality of life can be expected. Understanding 
patients’ preferences will provide valuable information to guide clinical practice and to allow the 
design of studies targeting treatment adherence and improved patient-centered outcomes. 
Patient preferences and health-care decision making 
Decision making in medicine can incorporate various perspectives depending on the decision 
context. Patient-centered outcomes research (PCOR) aims to elicit the patient’s viewpoint to 
generate evidence that can inform healthcare decision-makers.
 81
 As part of the trend towards 
patient-centered care and research, regulatory agencies have emphasized that patient preferences 
are an important factor in healthcare decision processes such as health technology assessments 
(HTAs) or benefit-risk assessments.
 82,83
 From a regulatory perspective, patients have experiential 
knowledge on their illness and/or health condition and can provide insights into living with the 
illness, technology or treatment.
 84
  
Patient-preferences and regulatory benefit-risk assessment 
To make regulatory decisions, the Food and Drug Administration (FDA) evaluates the safety, 
effectiveness, and quality of the drugs. Among other provisions, the Prescription Drug User Fee 
Act (PDUFA) and the Food and Drug Administration Safety and Innovation Act (FDASIA) 
require FDA to develop and implement a structured approach to benefit-risk decision making 
surrounding human drug, biological, and medical device products. The Agency emphasizes the 
need for transparency in decision making, and aims to be as quantitative as possible in 
considering available data. The evidence should support that the health benefits of using the 
product outweigh the potential risks and should demonstrate an absence of unreasonable health 




Patients have unique perspectives about the value of the probable benefits and the impact of 
potential risks of their medical treatments. In recognition of the patient experience, FDA’s Center 
for Drug Evaluation and Research (CDER) committed to establishing an initiative called Patient-
Focused Drug Development.
 86
 This initiative aims to obtain patients’ perspective on disease 
conditions and available treatments using a more systematic and expansive approach. In the first 
three years, public meetings on 20 disease areas
 87
 are being conducted with participants from 
FDA review divisions, patient-advocacy communities, and other interested stakeholders. These 
meeting with give reviewers a better understanding of challenges patients face in various 
therapeutic areas, including possible barriers to treatment. 
The first indication that quantitative evidence on patient preferences could be considered in FDA 
regulatory benefit-risk assessments came from guidance by the FDA Center for Devices and 
Radiological Health (CDRH).
 88
 In this guidance, CDRH listed “patient tolerance for risk and 
perspective on benefit” and heterogeneity in risk-tolerance as an additional factor that CDRH 
may consider in regulatory reviews. Subsequently, CDRH approved a weight-loss device based 
on a patient risk-tolerance study. In addition, CDRH has now established the Patient Preference 
Initiative
 89
 to provide the information, guidance, and framework necessary to incorporate patient 
preferences into the full spectrum of CDRH regulatory processes.  
Overview of the dissertation 
Due to chronic nature of the diabetes and the range of available treatment options and possible 
health outcomes, preferences for diabetes treatment are particularly sensitive and complex.
 75,76
 
Increasingly, treatment preferences are being recognized as critical in the evaluation and planning 
of quality healthcare.
 90-93
 However, while several institutions and guidance
 88
 now call for the use 
of patient preferences in diabetes treatment,
 77
 surprisingly little is known about patient 
preferences for diabetes treatment.
 28,76
   
 13 
The objective of this dissertation was to apply good-research practices throughout the stated-
preference study process (Figure 1-2). Through measuring the treatment preferences of patients 
with type 2 diabetes, we present a case study on good research practices in stated-preference 
methods research.  
Figure 1-2 Stated-preference study process 
 
 
Chapter 2 of this dissertation gave an overview of stated-preference methods. In Chapter 3, I 
demonstrated the application of a novel framework for the instrument development of a choice 
experiment to the development of a DCE that measures treatment preferences of patients with 
type 2 diabetes. In Chapter 4, I demonstrated good research practices to the experimental design 
and statistical analysis of a DCE and it will examine preference heterogeneity for type 2 diabetes 
treatment using a mixed logit model. In Chapter 5, I examined preference heterogeneity among 
patients with type 2 diabetes with different educational attainment. In Chapter 6, I provided an 
overview of tests that assess the validity and reliability of a discrete choice experiment.  Finally, 
in Chapter 7, I summarized the findings of the dissertation and discussed the limitations and 
policy implications of this research.  
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Stated-preference methods are qualitative and quantitative research methods that can be used to 
scientifically study the preferences, priorities, and values of patients and stakeholders. 
1-5
 Stated-
preference methods have been applied in market research, transportation, environmental policy, 




Choice models date back to Louis Thurston’s Law of Comparative Judgment which introduced 
the idea measuring outcomes through pairwise comparisons.
7,8
 Thurston also laid the groundwork 
for random utility theory by introducing the concept of a random variable to account for observed 
variability of responses.
9
 Lancaster coined the concept that goods are composed of various 
characteristics and that utility is derived from these characteristics rather than the good as a 
whole.
10
 Daniel McFadden extended Thurston’s theory of paired comparisons to account for 
comparisons among multiple options. He also developed the conditional logit model, the 




Stated preference methods can be used to model different scenarios and offer a flexible 
mechanism to evaluate products, or interventions. 
6,12
 Revealed preferences, which are obtained 
from the past behavior of consumers, are often complicated by constraints or selection 
mechanisms and might not be generalizable to other settings. 
1,13
 In addition, stated-preference 
methods can be used to value treatments that are not on the market yet.  
Random utility theory 
Stated preference methods are derived under the premise of a utility maximizing consumer and 




 and provides a rigorous approach to understand patients’ preferences and 
decisions. Random-utility theory assumes that an individual’s utility consists of two parts: a 
deterministic component that can be estimated from observed characteristics and a random 
component resulting from unobserved characteristics. If we assume that the random component is 
randomly drawn from the same distribution in each individual, we can use the deterministic 
component of the equation to estimate overall utility. A technical explanation follows. 
Random Utility Theory states that the utility (U) of individual n for a particular object i has two 
components, a deterministic/explainable component (Vmi), and a random component (εni) that 
consists of unobserved characteristics. The utility individual n obtains from for scenario i is: 
𝑈𝑛𝑖 = 𝑉𝑛𝑖 + 𝜀𝑛𝑖 (1) 
where Vni depends on characteristics of the object, Xni, and characteristics of the individual zn:  
𝑉𝑛𝑖 = 𝑥′𝑛𝑖𝛽 +  𝑧′𝑛𝛾(2) 
The probability that person n chooses object i over object j is: 
𝑃𝑛𝑖 = Pr(𝑈𝑛𝑖 > 𝑈𝑛𝑗) = Pr(𝑉𝑛𝑖 + 𝜀𝑛𝑖 > 𝑉𝑛𝑗 + 𝜀𝑛𝑗) = Pr(𝜀𝑛𝑗 − 𝜀𝑛𝑖 < 𝑉𝑛𝑖 − 𝑉𝑛𝑗) (3) 
From equation 3, statistical models can then be used to estimate preferences (see statistical 
analysis section). This approach has been the basis for many of the seminal applications of 
conjoint analysis in health
14-16
 and can easily be adapted to include more than two choice objects. 
  
 22 
Qualitative methods for stated preferences 
Stated-preference instruments collect and analyze quantitative data. However, qualitative 
methods are an important part of designing and testing a stated-preference instrument. 
17
 
Qualitative methods, such as pretesting of survey instruments, is common to achieve 
identification and refinement of attributes 
17,18
 and is recommended for stated preference 
instruments. A consensus report published by the International Society for Pharmacoeconomics 
and Outcome Research 
19
 provides broad guidance on how to conduct good conjoint-analysis 
research in healthcare. This study will explore a combination of methods, including literature 
review, semi-structured interviews, and patient-engagement to develop and test the instrument. 
Quantitative methods for stated preferences 
Stated-preferences methods revolve around the concept that goods or services (in this case 
treatments and medications) are composed of different characteristics, or attributes. 
8,11
 These 
attributes are taken into consideration by people and positive and negative weights are assigned. 
Participants make repeated choices about the goods and services. Based on these choices, 
inferences regarding preferences for the attributes relative to each other can be made. In addition, 
the tradeoffs people are willing to make between attributes can be estimated. These weights differ 
by individual based on demographic characteristics, values, and experiences. A person balances 







Figure 2-1 Conceptual model: Balancing positive and negative attributes 
 
 
Stated-preference methods have several advantages over other preference-elicitation techniques 
that involve direct engagement of patients and stakeholders. First, they can be used to derive 
weights for individual attributes of the product and to calculate rates at which patients are willing 
to trade between attributes.  Second, the preferences of different sub-groups of patients and 
stakeholders can be identified and compared using stratified analysis. 
20
 Third, the validity, 




Stated-preference methods include direct assessment questions, threshold technique, conjoint 
analysis and discrete-choice experiments (DCE), and best-worst scaling (BWS). This study 
makes use of DCE. DCEs are one of the most common form of stated-preference methods, 
22 
and 
guidelines have emerged for utilizing them. 
23-25
 In a DCE, a respondent is repeatedly presented 
with two distinct profiles and is asked to select the best profile. Figure 2-2 gives an example of a 
Adapted from: JJ, Louviere Hensher DA, Swait JD. Stated choice methods: Analysis and 
applications. Cambridge: Cambridge University Press; 2000. 
 24 
DCE choice task. 




Experimental design of stated-preference instruments remains one of the most controversial 
aspects of the application of stated-preference methods. 
26
 Experimental-design defines a 
systematic plan that determines the number of choice tasks and the variation in the attribute levels 
of the choice tasks. Efficient experimental designs maximize the precision of estimated choice-
model parameters for a given number of choice questions. 
26
  Many health studies have limited 
sample sizes due to resource constraints or the study of rare conditions that limit sample sizes to 
100 to 300 respondents. 
27
 In those circumstances, efficient experimental designs are critical to 
 25 
the success of the study. Three major components need to be considered in experimental design: 
model identification, statistical efficiency, and respondent efficiency. 
26
 
Model identification refers to the ability to obtain unbiased parameter estimates for every 
parameter in the model. To identify particular effects of interest, the experimental design must 
vary the relevant attribute levels within and across choice questions, include sufficient numbers of 
attribute-level combinations, and take into account if interaction effects need to get estimated. 
Statistical efficiency refers to minimizing the confidence intervals around parameter estimates. 
Efficiency will be minimized by a full factorial design that present all possible combinations of 
attributes and levels. However, the number of choice tasks necessary for a full factorial design 
quickly increases; at 2 attributes and 2 levels the number of combinations will be four, but at 4 
attributes and 3 levels this already increases to 81 combinations. Therefore, different designs need 
to be considered. Perfectly statistical efficient designs have three properties 1) balanced, meaning 
that each level appears equally often within an attribute, 2) orthogonal, meaning that each pair of 
levels appears equally often across all pairs of attributes within the design, and 3) minimal 
overlap, meaning that within a choice task pairs of levels should be the same a minimal amount of 
the time.  
Response efficiency refers to measurement error that results from respondents’ inattention to the 
choice questions or other influences. There may be study-design trade-offs between maximizing 
statistical efficiency and maximizing response efficiency. Maximizing the overall precision of the 
estimates requires balancing these two sources of potential error. 
28
  
Traditionally, the experimental design techniques used in health have focused on the a priori 
statistical efficiency of the experimental design, often trying to maximize the D-efficiency or D-
optimality.
29
 Such methods focus on ensuring that the comparison of the profiles is done to 
 26 
maintain orthogonality. As number of attributes and levels goes up, the number of choice tasks 
required for an orthogonal design tends increases as well. To give each respondent a manageable 
number of choice tasks, a respondent often only completes a subset, or block, of the experimental 
design. This blocking can introduce version bias, respondent inefficiency, and scale biases. 
30
  
Statistically efficient designs generally involve the use of uninformed priors (i.e., assuming the 
preference weights to be estimated are all zero). Because of this, they often compare options in 
which the preference would be obvious and no real tradeoff needs to occur (for example one 
option is very desirable while the other option is very undesirable). This lack of a trade-off within 
the task is a violation of the underlying theory
11
 and encourages respondents to answer with 
simplifying heuristics 
31
  (e.g., focusing on only one attribute).  
Modern experimental designs employ Bayesian techniques to maximize respondent efficiency. 
32
 
Respondent efficient designs devote less attention to the overall statistical efficiency and develop 
tasks that ensure that respondents are making real trade-offs. Such methods take into account the 
statistical models that will be used to estimate the choice model. 
33
 These designs also require the 
use of assumptions, priors, on the preferences. 
34
  Priors can be obtained from previous studies, or 
from a pilot study. This Bayesian approach requires that the efficiency of a design be evaluated 
over numerous different draws taken from the prior parameter distributions assumed in generating 






Aggregate analysis/conditional logit model 
Statistical analyses of DCEs quantify the importance of each attribute level in an individual’s 
choices relative to the other levels of the same attribute. These estimates can be used to determine 
what tradeoffs participants are willing to make between levels. They can also be used to 
determine the importance of the attribute relative to the other attribute, given the levels included 
in the choice experiment.  
The most common used methods to analyze choice data in health economics is the conditional 
logit model. 
22
 The conditional logit model assumes that there are no consistently different 
responses between individuals. 
35
 From random utility, once again let n present the individual, 
and i the choice scenario. Assume that 𝜀𝑛. are independently and identically distributed and 
follow a Type 1 extreme value distribution, then 𝜀𝑛𝑗 − 𝜀𝑛𝑖 follows a logistic distribution. The 
probability of person n choosing scenario i is (where 𝜎𝑛 is a scale parameter that is generally 
normalized to 1): 
𝑃𝑛𝑖 =  
exp(𝜎𝑛𝑉𝑛𝑖)
exp(V𝑛𝑖) + exp (V𝑛𝑗)
 (4) 






= exp(𝑉𝑛𝑖 −  𝑉𝑛𝑗)(5) 




) =  (𝑉𝑛𝑖 −  𝑉𝑛𝑗) = (𝑥′𝑛𝑖𝛽 +  𝑧′𝑛𝛾) − (𝑥
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Accounting for preference heterogeneity 
When the assumption of preference homogeneity is violated and preferences vary consistently 
across some respondents the conditional logit model may lead to biased results. Different 
techniques and models have been developed to account for preference heterogeneity.  
Mixed logit model 
The mixed logit model assumes that preferences are not fixed, but are random variables that are 
continuously distributed. 
36,37
. The mixed logit model captures the main effects as well as the 
distribution of each attribute level. It is increasingly used in the analysis of DCEs in healthcare. 
22
 
If 𝑓(𝛽|𝜃)is the density function of 𝛽, the in the mixed logit model, the probability of person n 
choosing scenario i is: 




which needs to be estimated using maximum simulated likelihood. 
Stratification 
Preference heterogeneity can be systematically examined via stratification. Stratification models 
assume that preferences are distributed in discrete groups. It separates study subjects into 
homogeneous groups based on observed characteristics (e.g., demographics) and estimates 
separate models or separate sets of coefficients (β’s) for each stratum. 
20
 Stratification methods 
can be combined with any other type of model including the conditional logit and mixed logit 
models. In addition, many researchers are familiar with the concept of stratification. 
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Tests for equivalence of stratified models 
When running a stratified model, the equivalence of preference parameters between the different 
models should be evaluated. All tests discussed below are outlined as Stata 13 (College Station, 
Texas) code in Appendix A.  
If the stratification is done by running separate models for the different groups, the models for the 
groups can be compared in their entirety using a log-likelihood ratio test
38
 or a Wald test. Paired 
t-tests can be used to test equivalence between the groups for each individual parameter estimate. 
If the model is stratified using interaction variables, a Chow test can be used to test for 
equivalence of between the groups for each individual parameter estimate as well for overall 
preference models. These procedures test whether the stratified models are equivalent, a p valued 
below the alpha threshold indicates that preferences are different for the specified models. 
In stated-preference models, the preference parameter is influenced by the scale parameter, which 
is inversely related to the error variance. The scale factor in a preference model is related to 
people’s choice consistency; the more consistent a person is in their choices, the higher their scale 
factor, and the more pronounced their preferences seem to be. This means that preference weights 
for different individuals might seem different only because the scale factor for these individuals is 
different. When evaluating the results of two stratified preference models, one therefore has to 
test whether observed preference differences are due to true underlying preference or due to the 
scale factor. This can be done using a two-step Swait-Louviere test described in Swait and 
Louviere (1993)
39
 and in Appendix A. 
Limitations of stratification 
Stratification requires a limiting assumption that preference heterogeneity can be accurately 
determined a priori by observed variables, 
40
 an assumption that is not met empirically. 
41,42
  In 
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addition, separate models (or interacted models) have to be estimated for each sub-group, which 
generally limits the number of subgroups that can be considered simultaneously.
11
 Finally, given 
this inability to conduct stratification on multiple indicators simultaneously, preference 
differences can be misclassified. 
Validity and reliability of stated-preference methods 
Validity is the extent to which preference measured in a stated-choice experiment reflect the true 
preferences of participants. However, due to the hypothetical nature of the choices made, 
validating stated-preference results is difficult. While there is no agreement on what constitutes a 
valid patient-preference study, methods to evaluate the quality of preference data exist. These 
methods include evaluating the consistency of choices and the use of simplifying choice 
heuristics, examining test-retest reliability, assessing the predictive power of preference data to 
predict choices, comparing preference results obtained using different elicitation techniques, and 
examining the face validity of the results and how they fit within previously conducted preference 
studies. 
43
 Currently no cut-off levels exist to determine when these test meet acceptable levels. 
Data collection  
The Internal Review Board of Johns Hopkins School of Public Health determined this study to be 
exempt from human subjects review (IRB 6001). The entire project was guided by the Diabetes 
Action Board (DAB), an advisory board that consisted of local Baltimore community members, 
people with type 2 diabetes, clinicians specializing in type 2 diabetes, regulators, stated-
preference methods experts, and other stakeholders. The DAB convened five times between 
March 2014 and November 2016 for the purposes of this study. 
This study included an instrument development stage (Paper 1), an instrument implementation 
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stage (Paper 2), and a data analysis stage (Paper 2-3). The instrument development stage made 
use of qualitative semi-structured pretesting interviews with participants with type 2 diabetes 
from the local Baltimore community. These interviews assessed the acceptability of the survey 
instrument to people with type 2 diabetes.  The implementation stage was subcontracted to GfK 
Knowledgepanel (see Appendix B); they recruited national participants and implemented the pilot 
and final survey instruments.  
Recruitment and sample selection 
Local recruitment and data collection was done by investigators at Johns Hopkins and by local 
members of the DAB. Recruitment occurred within the community and did not make use of any 
clinical knowledge. Recruitment was conducted through posting of flyers and by making use of 
DAB members’ personal networks. People interested in participating in the pretest interview 
called a member of the research staff to set up an appointment. Participants had to be over 18, and 
speak English. All participants reported having type 2 diabetes during recruitment, but some 
participants reported not having diabetes during the interviews themselves. Twenty-five 
Baltimore community members were recruited to participate in the pretest interviews. 
Recruitment for the pilot and national surveys was conducted by GfK Knowledgepanel, a panel 
that is nationally representative of the US population. Participants had to be over 18, have self-
reported physician diagnosed diabetes, and speak English or Spanish. 50 patients with type 2 
diabetes completed the pilot survey. 1103 patients with type 2 diabetes completed the main 
national survey. To allow for sub-group analysis, we oversampled patients with type 2 diabetes 
who are African American (n=254) and Latino (n=236) for the main survey. Oversampling is 
important as African Americans and Latinos have a high prevalence of diabetes 
44
 and have lower 
rates of adherence to treatment. 
45
 Most of this study focuses on the DCE that was completed by 
half the participants (pilot n=25, national n=552).   
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Design methodology and statistical analysis 
For the pilot survey, an orthogonal design with 81 choice tasks was used. For each participant, 12 
choice tasks were randomly chosen without replacement from the 81 available choice tasks.  
For the national survey, NGene 
32
 software was used to create a Bayesian D-efficient design. 
Priors for the Bayesian design were estimated from the pilot survey results (Table 2-1). Cost was 
assumed to be continuous and fixed. 
35
 The other attribute levels were assumed to be categorical 
and follow a uniform distribution. The MNL model was simulated with 200 random Halton draws 
and the resulting experimental design had a D-error of 0.06 with the estimated required minimum 
sample size (S-error) of 35 participants per survey version (105 total).   
Table 2-1 Priors from pilot test used for Bayesian D-efficient experimental design 
 
 [90% Conf. Interval] 
A1c level decrease 
 
1% [0.182, 0.646] 
0.5% Reference 
0% [-0.814, -0.352] 
Stable blood glucose 
 
6 days/wk [0.091, 0.574] 
4 days/wk Reference 
2 days/wk [-0.662, -0.187] 
Low blood glucose 
 
None* BWS [0.0483, 0.5099] 
During the day only  Reference 
During the day and at night* (Lloyd et al) [-0.6097, -.47088] 
Nausea  
None [0.1853, .6639] 
30 min/day Reference 
90 min/day [-0.6326, -.1727] 
Treatment burden 
 
1 pill/day [0.188, 0.659] 
2 pills/day Reference 
1 pill and 1 injection/day [-0.930, -0.432] 
Out-of-pocket cost -0.0352 
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The experimental design consisted of 48 forced-choice, paired-comparison choice tasks divided 
into three survey versions of 16 choice tasks each. Two holdout tasks were added to the 
experimental design. The first holdout task tested for choice consistency by repeating an earlier 
choice task. The second holdout task was the same across all three survey versions and was used 
to test for survey differences and was used to test the predictive capabilities of the choice model. 
Respondents were randomly assigned to one of three survey versions. The order of the choice 
tasks was randomized for each respondent.  
Data from the pilot survey was analyzed using the conditional logit model. Data from the national 
survey was analyzed using the mixed logit model. A conditional logit model was used for the 




Appendix A – Stata code with example tests for the equivalence of stratified models 
*This do file outlines several methods to conduct tests of equivalence between stratified models. It covers the Wald test, Chow test, and Likelihood ratio 
test. It also covers how to conduct a Swait-Louviere test to test for scale differences between groups. This is discrete choice experiment data has 6 
attributes each at three levels each (A1 A2 A3 B1 B2 B3 C1 C2 C3 D1 D2 D3 E1 E2 E3 F1 F2 F3). All model are estimated using effects coding. 
*Run Aggregate model 
global vars "A1e A2e B1e B2e C1e C2e D1e D2e E1e E2e F1e F2e " 
clogit response $vars, group(resptasktype) vce(cluster caseid) 
scalar la = e(ll) /*store for likelihood ratio test*/ 
*Run model for group 1 
clogit response $vars if group == 1, group(resptasktype) vce(cluster caseid) 
scalar l1 = e(ll) /*store for likelihood ratio test*/ 
*Run model for group 2 
clogit response $vars if group == 2, group(resptasktype) vce(cluster caseid) 
scalar l2 = e(ll) /*store for likelihood ratio test*/ 
*****Log likelihood test - tests whether the aggregate model has the same fit as the stratified models 
/*Likelihood ratio test : lr = -2 ln(L(m1)/L(m2)) = -2(ll(m1)-ll(m2)) 
m1 is the more restrictive model, m2 is the less restrictive model. When we compare aggregate models with stratified models, m2 is the sum of the 
likelihood ratios of the stratified models, it is less restrictive because we do not force the parameters for the groups to be the same*/ 
*get chi-squared value for log likelihood ratio 
di "chi2(2) = " -2 * (la - (l1 + l2))  
*chi-squared test for log likelihood ratio given the degrees of freedom (number of attribute levels in the model) 
di "Prob > chi2 = " chi2tail(12, -2*(la - (l1 + l2)))     
*******Wald test. We need to rerun the above models (quietly) without clustering by caseid (suest will not run clustered models) 
*Run model for group 1 
quietly: clogit response $vars if group == 1, group(resptasktype) 
estimates store model1 
*Run model for group 2 
quietly: clogit response $vars if group == 2, group(resptasktype) 
estimates store model2 
*run a seemingly unrelated estimation, this will allow you to run a Wald Test, specify to cluster by caseid 
suest model1 model2, vce(cluster caseid) 
*test to compare the two models in its entirety 
test [model1_response=model2_response] 
*test to compare each individual coefficient 
foreach var in $vars { 
test [model1_response]`var' = [model2_response]`var' 
}     
*CHOW test. Run a model with interaction variables 
*Create binary group variable and interaction variables 
gen group2 = 0 if group == 1 
replace group2 = 1 if group == 2 
global vars "A1e A2e B1e B2e C1e C2e D1e D2e E1e E2e F1e F2e e" 
foreach var in $vars{ 
gen `var'group2 = `var' * group2 
} 
global varsint "A1egroup2 A2egroup2 B1egroup2 B2egroup2 C1egroup2 C2egroup2 D1egroup2 D2egroup2 E1egroup2 E2egroup2 F1egroup2 
F2egroup2 G1egroup2 G2egroup2" 
*Run interaction model 
clogit response $vars $varsint, group(resptasktype) vce(cluster caseid) 
scalar li=e(ll) /*store for log likelihood test*/ 
estimates store model /*for Wald test*/ 
vce 
*test whether the interaction terms are significantly different from zero 
testparm A1egroup2 A2egroup2 B1egroup2 B2egroup2 C1egroup2 C2egroup2 D1egroup2 D2egroup2 E1egroup2 E2egroup2 F1egroup2 F2egroup2 
G1egroup2 G2egroup2 
*****SCALE TEST. Swait and Louviere test, see "The Role of the Scale Parameter in the Estimation and Comparison of Multinomial Logit Models"*/ 
/*Run clogithet model, see "help clogithet"  this is a model in which the parameters are set to be equal but the scale variable is allowed to vary */ 
clogithet response $vars, group(resptasktype) het(group) 
scalar lhet = e(ll) /*store for log likelihood test*/ 
estimates store modelhet /*for wald test*/ 
vce 
/* H1: B1 = B2 and mu1 = mu2 (where mu is the scale factor) 
First test H1a: B1 = B2 . H1a tests whether group one and group two have the same Betas, it tests whether the groups have the same preference 
parameters but different scale factors  If we fail to reject H1a, the two groups have the same underlying preferences and we need to move on to test H1b 
to see if there is a scale effect the degrees of freedom are equal  
di "chi2(2) = "-2*(lhet-(l1+l2)))   
/*Second test H1b: mu1 = mu2   (Only need to test H1b if we failed to reject H1a). H1b tests whether the scale factors (mu) are the same for the two 
groups If we fail to reject H1b, the scale factors are the same, there is no scale effect, and we fail to reject H1 (the preference parameters are the same 
for both groups and the scale factors are the same for both groups) If reject H1b, one of the groups has a larger error variance */ 
di "chi2(2) = " -2*(la-lhet) 
di "Prob > chi2 = "chi2tail(1, -2*(la-lhet)) 
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Appendix B - GfK KnowledgePanel 
GfK’s KnowledgePanel® is a nationally representative online panel that includes over 4,000 
patients with type 2 diabetes. It has detailed information on panel members’ age, gender, income, 
education, racial and location and can demonstrate. The GfK KnowledgePanel provides sampling 
coverage of 97% of the US adult population. 
46
 Panel members are randomly recruited by random 
direct-dial telephone (until 2009) or by address (since 2009), and households are provided with 
access to the Internet and hardware if needed. GfK surveys are based on a sampling frame that 
includes both listed and unlisted numbers, are not limited to current Internet users or computer 
owners, and does not accept self-selected volunteers. 
47
 GFK provided sampling weights so that 
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CHAPTER THREE  
-  
A FRAMEWORK FOR INSTRUMENT DEVELOPMENT OF A 
CHOICE EXPERIMENT: AN APPLICATION TO TYPE 2 DIABETES
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Objective: Choice experiments are increasingly used to obtain patient-preference information for 
regulatory benefit-risk assessments. Despite the importance of instrument design, there remains a 
paucity of literature applying good research principles. We applied a novel framework for 
instrument development of a choice experiment to measure type 2 diabetes treatment preferences. 
Methods: Applying the framework, we used evidence synthesis, expert consultation, stakeholder 
engagement, pretest interviews, and pilot testing to develop a best-worst scaling (BWS) and 
discrete choice experiment (DCE). We synthesized attributes from published DCEs for type 2 
diabetes, consulted clinical experts, engaged a national advisory board, conducted local cognitive 
interviews, and pilot tested a national survey.  
Results: From published DCEs (n=17), 10 attribute categories were extracted with cost (n=11) 
having the highest relative attribute importance (RAI) (range: 6-10). Clinical consultation and 
stakeholder engagement identified six attributes for inclusion. Cognitive pretesting with local 
diabetes patients (n=25) ensured comprehension of the choice experiment. Pilot testing with 
patients from a national sample (n=50) identified nausea as most important (RAI for DCE: 10, 
95% CI: 8.5, 11.5; RAI for BWS: 10, 95% CI: 8.9, 11.1). The developed choice experiment 
contained 6 attributes (A1c decrease, blood glucose stability, low blood glucose, nausea, 
additional medicine, and cost). 
Conclusion: The framework for instrument development of a choice experiment included five 
stages of development and incorporated multiple stakeholder perspectives. Further comparisons 
of instrument development approaches are needed to identify best practices. To facilitate 
comparisons, researchers need to be encouraged to publish or discuss their instrument 
development strategies and findings.  
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Introduction 
One key aspect in health economics involves the study of tradeoffs between scarce resources and 
the benefits of healthcare services. 
1
 While traditionally health economists have focused on the 
tradeoff between cost and effectiveness,
2
 more recently the tradeoff between benefits and risks of 
treatments have gained attention. 
3,4
 One of the challenges in these assessments is weighing the 








 regulatory agencies have 
emphasized that patient preferences are an important factor in regulatory benefit-risk decisions
3,8
 
and have released draft guidance 
9
 on incorporating patient preference information in benefit-risk 
assessment. Stated-preference methods can be used to quantify the tradeoffs people are willing to 
make, making them particularly suitable for benefit-risk analyses.
10
  





 and data analysis,
13
 few studies follow good practices for instrument 
development.
14
 The use of qualitative methods to develop choice experiments
15,16
 is well 
recognized and researchers continue to develop novel methods for instrument development.
17-19
 
However, the steps in developing stated-preference instruments have not been described 
comprehensively and few studies provide enough detail to replicate choice tasks.
14
 
This study utilized a novel framework for instrument development of a choice experiment to 
measure patient treatment preferences in type 2 diabetes. Type 2 diabetes presents an important 
case study given that it is a chronic condition with a growing literature on treatment 
preferences.
20-23
 This study examines the current findings on treatment preferences in type 2 
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diabetes and adds to this existing literature with a high quality preference study. In addition, this 
study aims to fill a gap in the stated-preference literature regarding instrument development.   
Methods 
This study applied the framework for instrument development of a choice experiment consisting 
of five stages: 1) Evidence synthesis, 2) Expert consultation, 3) Stakeholder engagement, 4) 
Pretest interviews, and 5) Pilot Testing. This approach combined the the current evidence base 
with expert and stakeholder engagement, in addition to patient-input and quantitative preference 
assessment (Table 3-1). We utilized this framework to develop and test two choice experiments, a 
BWS and a DCE, that measured treatment preferences of patients with type 2 diabetes.  
Table 3-1 Recommended stages of instrument development process of a choice experiment 
and application to type 2 diabetes experiment example 
 
Theoretical framework Application to type 2 diabetes 
Step Objective Description Results 
Evidence 
synthesis 
To gather existing 
evidence on preferences 
and utilize the existing 
literature to develop the 
instrument 
Compiled articles from 
literature reviews on 
treatment preferences of 
adults with T2DM. 
 Ten attribute categories 




To ensure clinical 
accuracy and relevance of 
the attributes and decision 
framework 
Convenience sample of 
clinical experts. Ensured 
clinical relevance of 
choice experiment  
 Experts selected 8 
attributes  
 Experts developed a 
decision framework  
Stakeholder 
engagement 
To engage stakeholders 
and gather input on 
patient-centeredness, and 





 The advisory board 




To ensure acceptability of 
the instrument to patients 
and to update the 
instrument based on 
participants’ feedback. 
Evaluated the choice 
experiment through 
interviews with adults 
with T2DM in 
Baltimore.  
 25 interviews  
 The choice experiment 
was continuously 
updated based on 
participant feedback 
Pilot testing To quantitatively test the 
instrument and to estimate 
attribute priors.  
Tested choice 
experiment with online, 
national panel of adults 
with T2DM. 
 27 participants 
completed the DCE (12 
tasks), 23 completed the 
BWS (18 tasks)  
 Nausea was valued 
highest, hypoglycemia 
lowest. 
    
 43 
Figure 3-1 details different activities performed during the instrument development process, 
which ranged from March 2013 until February 2016. This study was reviewed and deemed 
exempt from human subjects review by the Institutional Review Board at the Johns Hopkins 
Bloomberg School of Public Health (IRB # 6001). 







 was conducted to gather evidence on preferences in type 2 diabetes. 
Evidence on previously used attributes, study populations, instrument development, and study 
quality were used to inform attribute selection. The evidence review also placed this study in 
context of other preference studies in type 2 diabetes. 
All articles included in four previous literature reviews
20-23
 on preferences in type 2 diabetes were 
assessed for inclusion criteria. In addition, we conducted a search in PubMed to identify studies 
published after the last review had been conducted, between January 2015 and 2016. Keywords 
included: DCE, discrete choice experiment, and diabetes. Studies were included if they conducted 
a DCE or Conjoint Analysis (CA), if they assessed preferences for diabetes medication in people 
with type 2 diabetes, and if they were published in English. Studies were excluded if they 
assessed preferences for medications not used to treat diabetes, or if they assessed life-style 
interventions. 
Quality of each study was evaluated using the PREFS quality checklist, which assesses the 
purpose, responses, explanation, findings, and significance of preference studies.
21
 We extracted 
treatment attributes, levels, and preference estimates for each DCE. Attributes were categorized 
based on underlying clinical factors. Attributes that measured clinical factors not common to 
diabetes medications were grouped into a “side effects” category. We calculated RAI for each 
attribute in each DCE to estimate the importance of an attribute in the choice process relative to 
the other attributes in the study. If a study directly reported preference weight or attribute 
importance, RAI was calculated by subtracting the preference weight of the least preferred level 
of the attribute from its most preferred level.   
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If preference weights were not reported, rankings of the attributes or willingness-to-pay values 
(WTP) were adapted to reflect RAI. When attributes were ranked, the least preferred attribute was 
assigned a RAI of 1, the second least preferred attributed a RAI of 2, etc. This approach assumed 
that the RAIs were equally spaced between the most important and least important attribute in a 
study. 
If a study only reported WTP values, WTP for each attribute level was calculated. The difference 
between the highest and the lowest WTP within each attribute was taken to reflect the RAI. WTP 
presents the preference weight of an attribute level relative to the preference weight of cost. 
Taking the difference between the level with the largest and smallest WTP of each attribute 
presents the RAI of an attribute with respect to the preference weight for cost. Unfortunately, it is 
not possible to calculate the WTP (RAI relative to cost) for the cost attribute itself. 
The RAIs within each study were standardized on a ten-point scale, where ten represented the 
most important attribute in the study. RAIs directly extracted from the studies, and RAIs 
calculated from ranking or WTP were standardized in the same way. RAI is dependent on 
framing of the attributes, the attributes included in the choice experiment, the levels of the 
attribute, and the study population. Aggregating scores for RAI across studies therefore has 
limitations, but the range of RAI across studies provides an idea of how much patients value an 
attribute. 
Expert Consultation 
Clinical experts were consulted 
28
 to ensure accuracy of the survey instrument. Using a 
convenience sample, several local clinical experts, including two internal medicine practitioners, 
an RN with type 2 diabetes, and diabetes researchers, were involved in instrument development. 
The choice experiment was repeatedly discussed with clinical experts through in-person meetings 
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and email correspondence.  
Clinical experts helped categorize attributes for the evidence review. They also helped select 
attributes based on treatment guidelines
29
 and clinical relevance,
30,31
 and ensured the descriptions 
of attributes were accurate. Their expertise was used to create a clinically accurate decision 
framework to ensure that participant’s hypothetical choices approximated real-life choices. 
Results were presented to clinical experts after the pretest interviews and pilot test were 
completed and their input was used to revise the choice experiments. 
Stakeholder Engagement  
We formed a community advisory board, 
28
 the Diabetes Action Board (DAB), composed of 
patients with type 2 diabetes, local community representatives who served on another community 
research advisory board, stated-preference methods experts, and regulatory experts.
32
 Following 
the Patient-Centered Outcomes Research Institute’s (PCORI) engagement rubric,
33
 we engaged 
members of the DAB throughout the study. Engagement with the DAB took place via in-person 
meetings at the Johns Hopkins School of Public Health.  
DAB meetings educated members on the study purpose and stated-preference methods, and 
helped identify attributes. Stakeholders were engaged to gather input on patient-centeredness, and 
salience of the choice experiment. DAB members commented on and helped identify attributes. 
The DAB discussed, and edited the choice experiment for content and formatting. Separate 
meetings were held to educate the community board and to present results of pretest interviews 




The attributes selected through expert consultation and stakeholder engagement were combined 
into a DCE and BWS choice experiment for pretesting.
17,19
 The choice experiments were 
evaluated through in-person semi-structured cognitive interviews
34
 among patients with type 2 
diabetes in Baltimore, MD. Interviews were conducted by trained study personnel, recorded and 
transcribed. Participants were eligible if they were 18 or older, reported type 2 diabetes during the 
recruitment phone call, and spoke English.  
Recruitment occurred through the distribution of flyers throughout the community in locations 
such as apartment buildings, markets, and churches. Local members of the DAB also reached out 
to personal networks. Interested individuals called a member of the research team to set up an 
interview. Recruitment was conducted until the study team determined that satiation had been 
reached. This determination was based on the interviewers’ assessment that no new information 
to improve the survey was gathered from additional interviews. 
Participants were presented with an anonymous questionnaire to asses demographic and clinical 
characteristics. They were then presented with a paper version of the DCE and BWS. Participants 
were asked to read through the descriptions of the attributes and levels, complete the choice 
experiment, and verbalize responses, thoughts, and concerns about the content and formatting. 
Each pretest participant saw both DCE and BWS choice tasks and completed between 2 to 12 
choice tasks. No particular experimental design was utilized. 
Transcripts were analyzed using a five-item pretesting checklist. This checklist focused on i) 
comprehension of the attributes, ii) omitted attributes, iii) trade offs, iv) elicitation format, and v) 
study purpose. These items were assessed to ensure that participants would be able to 
successfully complete the choice experiment, to limit respondent burden, and to ensure patient-
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centeredness. The descriptions of the attributes were continuously updated based on feedback. 
Pilot testing 
After pretesting, the choice experiments were pilot tested
18,35
 to quantitatively test the instrument 
and to estimate attribute priors. The developed choice experiments were tested with members of 
an online, nationally representative panel.
36
 Participants were eligible to complete the survey if 
they were 18 or older, spoke English, and had self-reported type 2 diabetes. African Americans 
and Hispanics were oversampled. Due to limited sample size we did not analyze results 
separately for different subpopulations.  
Detailed descriptions of the attribute and levels (in particular A1c decrease) were included in the 
instrument and long term effects of poor glycemic control or glucose stability were explained. It 
was explained that a change in one attribute did not mean that another attribute changed in 
response.  
Participants were randomly assigned to complete either the DCE or the BWS. For the BWS, 
participants completed 16 choice tasks that followed a main-effects orthogonal design. For the 
DCE, participants completed 12 choice tasks; a main effects orthogonal design with 81 choice 
tasks was developed, then 12 tasks were randomly selected for each individual participant. 
Results were analyzed using effects coding and the conditional logit model with Stata 13 (College 




The choice experiment went through three iterations. Version 1 was developed through evidence 
synthesis, expert consultation, and stakeholder engagement and was pretested. Version 2 was 
updated after the pretest and was pilot tested. Version 3 was updated after the pilot (Table 3-2) 
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Table 3-2 Adjustments in attributes and levels included in the BWS and DCE experiments 
through two rounds of revisions 
 
Version 1 Version 2 - Pilot survey Version 3 - Final Survey 
Glycemic 
control 
A 1.1% reduction 
in HbA1c level  
A1c levels 
decrease  




1% – this is a 
large decrease 
A 0.7% reduction 
in HbA1c level 
0.5% – this is 
a moderate 
decrease 
0.5% – this is 
a moderate 
decrease 
A 0.3% reduction 
in HbA1c level 
0% – this is no 
decrease 





levels 6 days out 










6 days per 
week 
Stable glucose 
levels 4 days out 
of the week 
4 days per 
week 
4 days per 
week 
Stable glucose 
levels 2 days out 
of the week 
2 days per 
week 













1 additional low 
in a month 
1 per month During the 
day only 
2 additional lows 
in a month 
2 per month During the 
day and/or at 
night 
Nausea No nausea Nausea 
 
 
None Nausea None 
Moderate nausea 
that lasts for 1-2 
hours after you 
take a dose 






that lasts most of 
the day after you 
take a dose 






1 pill daily Treatment 
burden 
 
1 pill per day Treatment 
burden 
 
1 pill per day 
2 pills daily 2 pills per day 2 pills per day 
1 pill and 1 
injection daily 
1 pill and 1 
injection per 
day 





$10 in additional 
out-of pocket 
costs a month 
Medication 
costs  




$10 per month 
 
$30 in additional 
out-of pocket 
costs a month 
$30 per month 
 
$30 per month 
 
$50 in additional 
out-of pocket 
costs a month 





The four previous literature reviews combined reviewed 100 articles. Our PubMed search 
resulted in an additional 18 articles that were published in 2015 and 2016. 86 of 118 of articles 
were non-duplicate titles. 17 articles
38-54
 were included in the evidence review and had attributes 
extracted (Figure 3-2). Standardized RAIs could be calculated in 16 studies. Characteristics of 
included studies are presented in Table 3-3. 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ten attribute categories were extracted including cardiovascular (CVD) risk, glucose monitoring, 
quality of life, side effects, treatment burden, hypoglycemia, gastrointestinal effects, weight 
changes, glucose measures, and cost. Treatment burden (23 times), glucose measures (19 times), 
and hypoglycemia (17 times) were used most frequently. On average, cost was most important 
(median RAI: 10), although RAI could not be inferred for the two studies that only reported WTP 
values. Treatment burden and glucose levels had the most variable RAIs ranging from 1-10. 
Extracted attributes with RAIs are presented in Figure 3-3. 
 
Figure 3-3 Frequency and standardized relative attribute importance of diabetes 




Fig. 3-3 – Ten attributes from 12 Discrete Choice Experiment (DCE) studies are 
presented in order of standardized relative attribute importance (RAI). Number of 
times the attribute appeared across studies is indicated in parentheses behind the 
attribute name. An attribute could appear more than once in one study; it is therefore 
possible that an attribute appeared more than 12 times. The box around the median 
represents the interquartile range of RAI. Bars around the box indicate the minimum 
and maximum RAI of the attribute. 
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Expert consultation  
Clinical experts defined a decision context that asked participants to consider adding a 
hypothetical novel diabetes treatment to their current diabetes medications: “Suppose that your 
doctor says that your current diabetes medicine is not working to keep your blood sugar 
controlled. Your doctor recommends that you add another diabetes medicine to lower your A1c.” 
This decision framework provided a realistic decision for patients living with type 2 diabetes and 
ensured that participants made decisions from the perspective of having uncontrolled A1c levels. 
Clinical experts reviewed the extracted attributes from the evidence synthesis. After discussions 
about the clinical relevance of the attributes, they selected 8 attributes relevant to the decision 
framework, including glycemic control, hypoglycemia, weight changes, CVD risk, 
gastrointestinal side effects, blood glucose monitoring, administration frequency and mode of 
administration, and cost. Clinical experts helped identify 3 levels for each attribute and wrote 
descriptions for attributes and levels.  
Stakeholder engagement 
The DAB met three times to discuss instrument development: in March 2014, November 2014, 
and May 2015. Prior to the first DAB meeting, members from an existing community advisory 
board were invited to join the DAB. Between 13-20 DAB members participated in each DAB 
meeting. The first DAB meeting educated DAB members on stated-preference methods. 
Education efforts continued through September 2014 until the stakeholders had a full 
understanding of the project, and stated-preference methods. 
At the second meeting, the eight attributes selected by clinical experts were presented to the 
DAB. The DAB did not consider blood glucose monitoring to be important and this was 
corroborated by the evidence review (Figure 3-3). They asked that gastrointestinal side effects 
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was changed to nausea in line with more recently developed medications and to simplify the 
attribute. The DAB asked to exclude weight changes from the choice experiment because they 
did not think it was important to patients with type 2 diabetes. After considering labeling issues, 
in which weight gain or weight loss could be associated with specific medications, and based on 
the opinion of the clinical experts, weight was excluded. The DAB discussed difficulties with 
interpreting risk
55
 in relation to the CVD attributes and suggested to remove CVD risk from the 
attributes. The clinical experts agreed because of the limited number of diabetes medications 
associated with CVD risk. The DAB asked the study team to add glucose stability as a patient-
relevant attribute. 
The third DAB meeting was used to discuss pretest results and version 2 of the choice 
experiment. DAB members approved the choice experiment, attribute descriptions, and language 
use. DAB members were given the opportunity to individually review the developed choice 
experiment. Based on their review, edits to formatting and descriptions of A1c levels were made. 
At a separate meeting, regulatory experts recommended adding questions to identify subgroups 
for heterogeneity analyses. 
Pretest interviews 
After expert consultation and stakeholder engagement, we selected six attributes at three levels 
each
56
 for pretesting. Attributes included: A1c decrease, blood glucose stability, additional low 
blood glucose, nausea, additional medicine, and additional out-of-pocket cost (Table 3-2). 
Twenty-five interviews were conducted in February and March 2015 in Baltimore. Interviews 
lasted between 20-60 minutes. Demographic characteristics of the study participants are presented 
in Table 3-4. Qualitative findings of the pretesting checklist are presented in Table 3-5. 
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Table 3-4 Demographic and clinical characteristics of pretest and pilot participants 
 Pretest Pilot 
Characteristic Subjects N=25 Subjects N=50 
Gender – no. (proportion)   
Male 9 (0.36) 27 (0.54) 
Age (years) – mean (range) 57 (31-89) 64 (32-82) 
Race/ethnicity   
Non-Hispanic White 2 (0.08) 22 (0.44) 
Hispanic or Latino 2  (0.08) 13 (0.24) 
Black or African American 20 (0.80) 12 (0.26) 
Other 1 (0.04) 3 (0.06) 
Education – no. (proportion)   
No High School diploma 2 (0.08) 3 (0.06) 
High School degree/GED 7 (0.28) 18 (0.36) 
Some college  11 (0.44) 21 (0.42) 
Bachelor degree or higher 5 (0.20) 8 (0.16) 
Diabetes diagnosis – no. (proportion)
a
 23 (0.92) 50 (1.00) 
Years with diabetes – mean (range) 10 (0-37) 13 (0-62) 
Self-reported A1C– no. (proportion)   
Greater than 8.0% 4 (0.17) 8 (0.16) 
Between 7.1-7.9% 5 (0.21) 12 (0.24) 
Smaller than 7.0% 8 (0.33) 21 (0.42) 
Don’t know 7 (0.29) 9 (0.18) 
Medication – no. (proportion)   
A pill 14 (0.48) 32 (0.64) 
An injection 11 (0.38) 14 (0.28) 
None 4 (0.14) 4 (0.08) 
a
During the pretest interviews some participants reported that they did not have diabetes 
during a self-administered survey that was not part of eligibility requirements. 
 
Pretest participants understood the attributes presented, but some participants had difficulty 
interpreting A1c decrease. Participants liked the presentation of additional low blood glucose 
because it contained detailed descriptions of symptoms. Names and descriptions of the attributes 
were adapted throughout the pretesting process to maximize participants’ understanding. 
Descriptions were made more comprehensive and listed short and long-term side effects. A1c 
levels were described in more detail. We added an explanation that none of the attributes were 
correlated; specifically, higher A1c decrease did not mean better glucose stability.  
Participants thought that the attributes were relevant and were willing to make tradeoffs. Five 
participants (20%) mentioned omitted attributes such as severe hypoglycemia, amputation, blood 
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glucose monitoring, and diarrhea. While cost was important to participants, they were willing to 
pay more if the medicine offered sufficient benefits and small risks. To ensure proper trading, the 
levels for nausea were adapted to eliminate interaction effects with additional medicine. In 
addition, the levels for A1c decrease received qualitative descriptors. No attributes were added or 
omitted based on participants’ feedback. 
Participants easily engaged with the elicitation method. Participants did not express a preference 
for the DCE or BWS; some participants preferred the BWS because it presented less information, 
others preferred the DCE because they thought it related to making choices in their everyday life. 
When asked how many DCE or BWS tasks participants thought they could complete in one 
sitting estimations varied from four to twenty. Based on participants’ feedback, we put attributes 
on the left and treatment profiles on the right in the choice tasks. Participants understood the 
purpose of the study and hoped that it would lead to the development of better medications. One 










The choice experiment for the pilot test was developed based on the pretest interviews and 
reviewed by clinical experts and DAB members. Figure 3-4 and Figure 3-5 present an example 
task of the DCE and the BWS employed in the pilot test. Fifty participants from the online panel 
completed the pilot survey in July 2015. Participants lived across the US (data not shown). 
Twenty-three participants completed the BWS and twenty-seven completed the DCE. 
Characteristics of pilot participants are presented in Table 3-4. Our participants were more likely 
to take medication than a 2011 national sample (92% v. 81% respectively
57
) and were living with 
diabetes slightly longer than the 2011 sample (12 years v. 11.4 years 
58
). All 50 participants fully 
completed either the BWS or DCE and were included in the analysis.  
Figure 3-4 Example of a Discrete Choice Experiment Choice Task 
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Figure 3-5 Example of a Best-Worst Scaling Choice Task 
 
 
Figure 3-6 represents the preference weights for each attribute level (DCE or BWS). With the 
exception of hypoglycemia in the DCE, higher preference weights were associated with better 
clinical outcomes or lower harm and lower preference weights were associated with worse 
outcomes or higher harm. Nausea had the highest RAI for both the DCE (RAI: 10, 95% CI: 8.5, 
11.5) and BWS (RAI: 10, 95% CI: 8.9, 11.1). Correlation between the results of the DCE and 
BWS was high (rho>0.9). 
Based on the pilot test, the choice experiment was adapted. The duration of nausea was lowered 
from 4 and 2 hours to 90 and 30 minutes. In addition, hypoglycemia was adapted to measure 
preferences for daytime and nighttime hypoglycemic events (Table 3-2). These changes were 
made in consultation with the clinical experts in an attempt to increase utility balance and allow 




Figure 3-6 Preference weights and relative attribute importance for diabetes medication 




Fig. 6 – Preference weights and relative attribute importance (RAI) from the pilot test for each 
attribute (level) are indicated both for the BWS and DCE experiments. Brackets indicate the 
95% confidence interval for each preference weight and RAI. Within each attribute, more 
preferred outcomes are indicated by higher preference weights and less preferred outcomes 
with lower preference weights. RAI indicates the difference between the most preferred and 





 and mixed methods
64
 have been previously used to elicit patient preferences and 
are recognized to provide useful information for the development of stated-preference 
instruments.
65
 The steps applied in this framework for the development of a choice experiment 
have been considered in previous work,
66
 but have not yet been combined in this way. Coast et al. 
(2012)
16
 recognize two phases in choice experiment development: conceptual development and 
refinement of language. The first three steps in the framework apply to conceptual development, 
while the fourth pretesting step concerns refinement of language. The framework also includes 
pilot testing as a third phase. The insights gained from the pilot test resulted in significant 
changes to the choice experiment, suggesting that qualitative pretesting and quantitative pilot 
testing both play a crucial role in instrument development. 
This is it is the first study to synthesize the DCE literature on patient preferences in type 2 
diabetes. Previous literature reviews have compiled the preference literature for diabetes,
21,22
  
ranked attributes within studies,
20
 and created standardized importance scores,
23
 but none 
aggregated importance scores across studies.  
With the advent of patient-centered benefit-risk assessment and the inclusion of patient 
preference information, the demand for patient-preference studies may increase dramatically. As 
the evidence base on patient preferences grows, comprehensive evidence reviews will be needed 
to place the results of preference studies in context of the existing literature and help researchers 
build on existing research. In addition, comparisons stated-preference studies can help establish 
the reliability of preference studies.  
In this study, we showed that is possible to identify a range of attributes from previously 
conducted DCEs if a significant literature exists. Attributes can also be extracted from other 
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literature sources such as clinical trials
39
 or previous qualitative studies.
18
 Since it is likely that 
more attributes will be identified in the literature than can be included in a choice experiment, 
expert consultation and stakeholder engagement can help narrow down attributes for inclusion. 
The framework applied in this study is adaptable to a variety of needs. The approach to 
instrument development used in this study focused on evidence-synthesis, which is appropriate 
for benefit-risk assessments in the pre-market approval space. The framework can be easily 
adapted to place more emphasis on stakeholder engagement, making it more suitable to patient-
focused drug development initiatives.
67
 
This study had several limitations. First, expert consultation was informal and made use of a 
convenience sample of clinical experts. Instrument development could be improved through a 
more formal expert consultation process, for example by creating an expert advisory board. The 
number of experts and the formality of the engagement should depend on the research question 
and clinical area of interest. A particularly complicated or controversial clinical area might need 
more clinical experts engaged in a more formal manner than a relatively well-known clinical area. 
While many current studies make us of one or two thought experts in the field, this study 
attempted to incorporate a larger variety of perspectives. The engagement of a variety of experts 
is critical to ensure that different perspectives are represented.  
Second, the stakeholder engagement process was long and spanned from March 2013, when 
education activities began, to October 2015, when the national survey launched. Engagement 
continues to the present day through engagement/dissemination activities with the DAB. DAB 
meetings were generally attended by variety of people and not every DAB members was able to 
attend every meeting. 
Third, pretest participants were not representative of the US population and were recruited from 
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local DAB members’ networks. Issues identified by urban residents in Baltimore may differ from 
those in other populations and this may have influenced instrument development. More targeted 
recruitment may have resulted in a smaller but more diverse sample.  
Fourth, patients might not be aware of certain treatment characteristics and might therefore not 
identify these characteristics during semi-structured interviews. To minimize this limitation, we 
could have asked pretest participants about certain attributes, such as CVD risk, directly.  
Fifth, changes made to the survey after pilot testing were not further tested before they were 
incorporated into the final survey. It is important to test major changes to the choice experiments, 
but most researchers work with limited resources and time. When to finish testing the choice 
experiment is largely a value judgment made by the research team. Furthermore, the changes 
made after the pilot test were approved by clinical experts and stakeholders. 
Additional research on the instrument development of choice experiments should be conducted to 
move towards a set of best practices. Studies should be conducted to determine how engaging 
different stakeholders from different backgrounds influences instrument development. The choice 
experiment developed in this study will be administered to a national sample of patients with type 
2 diabetes. The results obtained in the pilot test will inform a Bayesian, D-efficient design in 
NGene.
68
 The results from the national study will be used to estimate preferences of patients with 
type 2 diabetes as well as identify subgroups of patients
55
 with different preference profiles based 
on stratification and segmentation
69




This paper applies a framework for instrument development of a choice experiment using five 
stages. As choice experiments and other stated-preference methods are incorporated in regulatory 
decision making such as benefit-risk analysis, greater attention must be placed on the 
development of these instruments. While our approach is relatively novel, additional comparisons 
of approaches are needed to identify best practices for instrument development. To facilitate these 
comparisons, preference researchers should be encouraged to publish or discuss their instrument 
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CHAPTER FOUR  
-  
CONDUCTING A DISCRETE-CHOICE EXPERIMENT STUDY 
FOLLOWING RECOMMENDATIONS FOR GOOD RESEARCH 
PRACTICES: AN APPLICATION TO ELICITING PATIENT 
PREFERENCES FOR DIABETES TREATMENTS 




Objective: Given recent methodological advances in stated-preference methods, we sought to 
consolidate and illustrate good research practices in healthcare in a study measuring patient 
preferences for type 2 diabetes medications. 
Methods: ISPOR good research practices and other recommendations were used to conduct a 
discrete-choice experiment. Members of a United States online panel with type 2 diabetes 
completed a web-enabled, self-administered survey that elicited choices between treatment 
profile pairs with six attributes at three possible levels each. A D-efficient experimental design 
blocked 48 choice tasks into three 16-task surveys. Preference estimates were obtained using 
mixed-logit estimation and used to calculate treatment choice probabilities.  
 
Results: 552 participants (51% male) completed the survey. Participants were more likely to take 
medication (93%) than a national sample (81%). Avoiding 90 minutes of nausea was valued 
highest (Mean: -10.00, 95% confidence interval (CI): -10.53, -9.47). Participants wanted to avoid 
hypoglycemia during the day and/or night (Mean: -3.87, CI: -4.32, -3.42) or 1 pill and 1 
injection/day (Mean: -7.04, CI: -7.63, -6.45). Participants preferred stable blood glucose 6 
days/week (Mean: 4.63, CI: 4.15, 5.12) and a 1% decrease in A1c (Mean: 5.74, CI: 5.22, 6.25). If 
cost increased by one dollar, the probability that a treatment profile would be chosen decreased 
by 1%.  
Conclusion: Despite numerous efforts to produce recommendations for stated-preference 
methods, ambiguity surrounding good practices remains. Partially due to lack of evidence 
comparing study designs, various judgments need to be made when conducting stated-preference 




Patient-centered outcomes research (PCOR) aims to elicit patients’ viewpoints to inform 
healthcare decision making. 
1
 The value of patients’ experiential knowledge about living with 
their health condition to healthcare decision making is increasingly recognized. 
2-4
 Several 
countries have initiated patient-centered approaches to regulatory decision making. 
5-7
 
There are several approaches to evaluating patient preferences. 
2,8,9
 Qualitative information may 
be sufficient for relatively straightforward decisions, but stated-preference methods help to 
quantify preferences in support of more difficult assessments. 
10
 Many stated-preference methods 
have the advantage of measuring preferences in a controlled experimental setting. 
11
 They can 
also be used to estimate specific tradeoffs people are willing to make in treatment choices. 
12
 
The increased role of patient-preference information in patient-centered decision making requires 
preference studies that meet standards of transparency consistent with clinical-evidence. 
13
 Due to 
a lack of thoroughness and transparency in reporting, it is often not clear how good research 
practices are implemented. 
14
 Therefore, we sought to quantify patient preferences following good 
research practices, and to demonstrate the application of good research practices to the 
development, implementation, analysis, and dissemination of this study. 
We applied recommendations on stated-preference studies in a healthcare setting as part of a 
study focused on measuring treatment preferences of patients with type 2 diabetes mellitus. 
15
 By 
choosing a disease area for which a preference research base exists, 
16-19
 we could place our study 
in context of the existing diabetes-preference literature. While type 2 diabetes is an important 
case study, this research will advance methods that should have broad generalizability across 




This discrete-choice experiment (DCE) survey was developed by consolidating various 
recommendations on conducting stated-preference studies in healthcare. 
8,12-14,17,20-31
  We followed 
reporting recommendations of the ISPOR Conjoint Analysis Task Force checklist for good 
research practices 
32
 because it provides consensus-based recommendations for the different 
phases of a stated-preference study. We also used the Task Force’s recommendations on 
experimental design, 
11
 and statistical analysis. 
33
 Table 4-1 presents how each item in this 
checklist was addressed and which recommendations can be referenced for additional 
information.  
I. Research question 
Defining a specific research question is not only the first step in a stated-preference study, but it 
guides all subsequent decisions. 
8
 This study measured the treatment preferences of patients with 
type 2 diabetes mellitus. Like previous contributions, 
34-44
 we estimated a set of preference 
weights for medication attributes. We then examined how each attribute level affected the 
probability that a treatment profile would be chosen. Based on stakeholder input, 
28
 patients with 
type 2 diabetes were asked to consider the perspective of a patient that needed to start using an 
additional diabetes medicine. This is a common clinical occurrence in diabetes treatment 
45,46
 and 
it helped standardize the choice scenario for participants with different disease histories. We 
chose to use a choice-based conjoint analysis, or a DCE, to allow for the examination of trade-



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































II. Attributes and levels  
Identifying relevant preference attributes and levels is key to designing any stated-preference 
study. 
27
 All relevant attributes and levels for this study were identified from the diabetes 
preference literature 
28
 and supplemented with qualitative and quantitative data 
8,12,21
 obtained by  
engaging diverse stakeholders (clinicians and diabetes researchers, stated-preference and 
regulatory experts, and people with type 2 diabetes). We conducted qualitative pretest interviews 
with people with type 2 diabetes living in the local community (n = 25) to refine the survey and to 
assess the salience of the attributes to the treatment decision. We conducted quantitative pilot 
testing with a national sample of people living with type 2 diabetes (n = 27) to obtain priors for 
the attribute level. We selected 6 attributes, which consisted of treatment benefits, harms, and 
burdens, at 3 possible levels each (the range most reported in the literature 
20
). Other recent 
development processes have placed more focus on community engagement. 
25,26
 Further details 
regarding survey development were previously reported. 
28
 
III. Construction of tasks 
Construction of the choice tasks determines if the generated data can be used to answer the 
research question. 
23
 We tested multiple choice-elicitation formats, 
28
 and chose a full-profile, 
forced-choice choice tasks between two treatment profiles in which participants indicated which 
treatment they would prefer to take. This set-up allowed for the elicitation of acceptable tradeoffs 
people between different treatment attributes. In healthcare, full-profile, forced-choice, and paired 
treatment profiles are common and considered good research practice. 
32
 If the number of 
attributes is low enough that participants can reasonably complete a full-profile task, these 
maximize information about trade-offs. 
24
 We did not allow participants to select an opt-out to 
maximize information obtained about tradeoffs 
24
 and to reduce biases in how participants 
evaluate an opt-out option. 
23
 Given that forced-choice scenarios might not be realistic, we could 
 76 
have included two steps in which the forced-choice was followed by an opt-out option. 
47
 An 
example choice task with decision scenario is shown Figure 4-1.  
 
Figure 4-1 Example of a discrete-choice experiment choice task 
 
IV. Experimental design 




 software used 
row-based swapping to create a Bayesian D-efficient design.
49
 D-efficient designs maximize the 
precision of the estimated parameters given a set number of choice tasks.
50
. Priors for the 
Bayesian design were estimated from pilot results. Cost was assumed to be continuous and fixed
51
 
and the other attribute levels were assumed to be categorical and uniformly distributed. This 
design was sufficient to estimate main preference effects without interactions between attributes 
and was sufficient to answer our research question. A more advanced design approach could have 
been to adjust the levels of the cost attribute until a predicted choice probability of 75% for one of 
the treatment profiles and 25% of the other profile was achieved. 
 77 
The design contained 48 choice tasks. Attribute balance was achieved but cost levels overlapped 
for 14 tasks. The design was blocked into three 16-task survey versions. Versions were selected 
to minimize average correlation between the versions and attribute levels. While, blocking 
reduces response burden, other desirable properties of the experimental design may not hold for 
individual blocks. 
11
 Two additional tasks were added to each survey version. The first was a 
repeat-task that tested choice consistency. The second was a holdout-task that was the same 
across all three of the survey versions and tested for equivalence in the choices across survey 
versions. Participants completed 18 choice tasks, which is slightly more than average, 
20
 but was 
deemed appropriate based on pilot results.  
V. Preference elicitation 
Various preference elicitation methods with different design and analytical approaches can be 
used to answer different research questions among different study populations. 
2
 We conducted a 
DCE because it is the most commonly used stated-preference method in healthcare 
20
 with good 
research practices recommendations available (Table 4-1). In addition, it allowed us to place 
preference results in the context of other diabetes DCEs. 
28,52
 
To encourage participants to pay attention to the choice tasks, they were told that we were 
interested in measuring their preferences to help improve medical practice. We also included 
cheap talk 
53
 and a $10 cash equivalence to motivate participants. At the start of the choice tasks 
participants were asked to keep in mind the choice scenario. This perspective could have been 
reinforced throughout, but we did not do this to reduce reading time. Three questions asked 
participants to evaluate the choice tasks for ease of understanding, answering, and choice 
consistency. To limit response burden, we did not include warm-up questions or choice tasks that 
tested choice task understanding. We felt participants understood how to complete the choice 




VI. Instrument design 
As a DCE is part of a larger survey, general good research practices for survey design apply.
54,55
 
Demographic and clinical background information was collected so characteristics of respondents 
could be examined and subgroup analyses could be performed Table 4-2. The survey included 
detailed descriptions on attributes and levels and an explanation of the decision scenario
23
 to 
ensure that participants understood each attribute, the choice they were asked to make, and how 
to complete the choice tasks (Appendix C).  
Respondents were randomly assigned to one of three survey versions
23
 and the order of the choice 
tasks was randomized for each respondent to minimize order effect.
56
 Response burden for the 
overall survey was assessed during pretesting and pilot testing and it was found that participants 
could complete all parts of the survey.
28
 The finalized survey was translated into Spanish and 
reviewed by an independent, native Spanish speaker. Due to time constraints, the Spanish version 
of the survey was not pretested or pilot tested.  
VII. Data collection 
An appropriate data collection plan ensures that the research question can be answered for the 
population of interest.
13
 Participants were recruited via email from a national online panel that 
includes over 4,000 patients with type 2 diabetes.
57
 Participants were eligible if they were at least 
18 years old, had self-reported physician-diagnosed type 2 diabetes, and spoke English or 
Spanish. African Americans and Latinos were oversampled to ensure a large enough sample size 
given the high prevalence of diabetes in these populations.
58,59
 We did not exclude participants 
based on medication use because we were not interested in evaluating preferences for a specific 
medication. Representativeness of the study sample is a desirable property,
60
 but tradeoffs with 
response rate, time in the field, and cost of survey administration exist.  
 79 
We targeted a sample size of 500 to ensure sufficient power. Sample size calculations in stated-
preference methods often rely on rules of thumb
23,61,62
 or on assumptions regarding preference 
estimates.
30
 Participants self-administered the survey through an online platform October 9-24, 
2015. An online survey was chosen to reach a large sample of participants across the US. Paper 
based surveys might be more successful in reaching older populations and interviewer-led 
surveys may improve the quality of the data, but they take longer, are more expensive, and can be 
more difficult to administer across a wide geographic area. The Johns Hopkins School of Public 
Health IRB determined this study exempt from human subjects review (IRB 6001) and all data 
collection, such as de-identifying data and allowing participants to stop the survey at any time, 
was done in accordance with ethical standards.  
VIII. Statistical analysis 
Given their different characteristics, different analytical methods are appropriate to use in 
different settings.
33
 In this study, respondent characteristics for demographic and clinical 
characteristics were examined and compared to a national population. No formal tests of 
equivalence were conducted. We examined rates of non-response, task non-attendance, attribute 
dominance, and self-reported evaluations of the choice tasks. The two additional tasks were 
excluded from the main analysis and were used to test for quality of the responses in terms of 
choice consistency and survey version equivalence. 
The choice model was estimated using the mixed logit model with panel data
33
 to adjust for 
within-subject correlation
63,64
 and account for unobserved preference heterogeneity.
33
 The model 
was estimated using the mixlogit command with 1000 random Halton draws in Stata 13 (College 
Station, TX). No interaction terms were included. Cost was included as a continuous and fixed 
variable. 
51
 The other attributes were included as effects-coded categorical variables that we 
assumed to be normally distributed. This assumption was based on convenience, as appropriate 
 80 
assumptions for these distributions remain ambiguous.
23,24,33,51
 We chose to use effects coding to 
account for non-linearities.
24
 The level of each attribute that we expected to be most neutral was 
used as the omitted or reference attribute parameter. Effects coding was chosen over dummy 
coding as it allows for the calculation of standard errors for the omitted category.
33
 
Preference estimates from the choice model can be used to calculate the probability that a 
treatment profile will be chosen given its attribute levels.
33
 We used the mixlpred command in 
Stata to calculate the change in choice probability for a treatment profile given that one attribute 




IX. Results and conclusions 
Implications of the study results include a careful consideration of the uncertainty in the data and 
limitations of the study.
32
 The coefficients reported in this study represent relative-importance or 
preference estimates, the amount of weight people place on the attribute level. 95% confidence 
intervals are reported to account for measurement uncertainty and to examine whether attribute 
levels were statistically different from each other. We expect the preference estimates to be most 
positive/least negative for the levels with highest benefit/lowest harm and most negative/least 
positive for the levels with lowest benefit/highest harm.
21
 
We examined how participants value the benefits of diabetes medication as opposed to the harms 
or burden/cost of diabetes medication to determine what medication aspects they place more 





 as this was not needed to address our research question. We compared 
results from this study to published DCEs in diabetes
28
 to evaluate external validity. We placed 
the study within existing good research practices (Table 4-1) and discussed limitations in the 
discussion. 
 81 
X. Study presentation 
Transparent reporting and clear explanations of the objective, methods, results, and conclusions 
are crucial in conducting a stated-preference study,
14
 but can be hampered by publication word 
limits. This study was targeted towards researchers interested in conducting stated-preference 
research and attempts to explain issues and terminology unique to stated-preference studies. To 
inform readers of the survey instrument, this paper includes a sample choice-task and a shortened 
version of the survey instrument in Appendix C. We briefly discuss, but do not elaborate on 
implications for diabetes clinical practice or regulatory decision making as this study focused on 
applying good research practices.  
We present preference results in Table 4-3 and Figure 4-2. For ease of interpretation we shifted 
the coefficients of each attribute so that the coefficient of the lowest benefit/lowest harm was 
equal to zero and we rescaled the coefficients so that the absolute value of the most important 
outcome equaled ten. 
65
 Furthermore, we provide results in terms of the predicted change in 
treatment profile choice probability.
31
 Figure 4-2 also provides a visual representation of the 
distributions of the preference estimates to illustrate individual preference heterogeneity. 
Results  
552 people, 51% male, completed the DCE. Sample characteristics are presented in Table 4-2. 
Mean age of the participants was 61.3 years old. Participants were more educated than the 
national population between 45-64 years of age.
66
 Our participants were more likely to take 
medication than a 2011 national sample (93% v. 81% respectively)
67
 and were living with 










Age - years  
      Mean 61.30 
     Range (24, 91) 
Gender – N (%)  
Male  279 (0.51) 
Female  273 (0.49) 
Race – N (%)  
White  289 (0.52) 
Black  126 (0.23) 
Hispanic  119 (0.22) 
Other  18 (0.03) 
Education – N (%)  
Less than high school  43 (0.08) 
High school  188 (0.34) 
Some college 156  (0.28) 
Bachelor’s degree or higher 165 (0.30) 
Income – N (%)  
< 25,000  132 (0.24) 
25,000 – 50,000  148 (0.27) 
50,000 – 74,999  111 (0.20) 
≥ 75,000  161 (0.29) 
Time since diabetes diagnosis - years  
Mean 12.6 
Range (11.4, 13.7) 
Self-Reported Health – N (%)  
Excellent 33 (.06) 
Very good 158 (.29) 
Good 232 (0.42) 
Fair 106 (0.19) 
Poor 23 (0.04) 
No. Hypoglycemic events in last 6 months – N (%)  
None 293 (0.53) 
1 time 80 (0.14) 
2-5 times 134 (0.24) 
> 5 times 45 (0.08) 
Most recent A1c level – N (%)  
> 9.0% 21 (0.04) 
≥ 8.0%, but < 9.0% 59 (0.11) 
≥ 7.0%, but < 8.0% 153 (0.28) 
< 7.0% 228 (0.41) 
Don’t know 89 (0.16) 
Type of diabetes medicine used – N (%)  
No prescription medicine 37 (0.07) 
Only pills 345 (0.63) 
Only injections/shots 42 (0.08) 




Participants took 21 minutes (median, range: 4-18,939 min) to complete the entire survey with 10 
minutes (median, range: 0.9-192 min) for the DCE. 71% of participants agreed or strongly agreed 
that the choice tasks were easy to understand, 64% (strongly) agreed that the choice tasks were 
easy to answer, and 80% (strongly) agreed that they answered in a way consistent with their 
preference. 88 choice tasks were not completed among 9 participants (1.6%). Three participants 
(0.6%) always selected “Medicine A” or “Medicine B” across all choice tasks indicating task 
non-attendance. 81 participants (15.7%) displayed attribute dominance by always choosing the 
alternative with the better level of one attribute. 76% of participants answered the repeat-task 
consistently. Probability of choosing Treatment A for the holdout task was not statistically 
different across version 1 (0.59), version 2 (0.62) and version 3 (0.68) (p=0.15).  Analyses 
include all participants who completed at least one choice task. Excluding certain participants 




The results from the mixed logit model are presented in Figure 4-2 and Table 4-3. Given the 
significant standard deviation (SD) for all but two attribute levels (6 days of stable blood glucose 
(SD: 0.00, p=0.99) and hypoglycemia during the day and/or night (SD: 0.98, p=0.07)), the 
assumption of random parameters was appropriate and indicated that there was significant 
preference heterogeneity.  
Preference estimates moved in the direction hypothesized. Avoiding 90 minutes of nausea was 
valued highest by participants (rescaled mean preference estimate (Mean): -10.00, 95% 
Confidence interval (CI): -10.53, -9.47). Participants wanted to avoid hypoglycemia during the 
day and/or night (Mean: -3.87, CI: -4.32, -3.42) or 1 pill and 1 injection/day (Mean: -7.04, CI: -
7.63, -6.45). Participants showed a preference for stable blood glucose 6 days/week (Mean: 4.63, 
CI: 4.15, 5.12). Participants did not show a difference in preference for a 0.5% decrease in A1c 
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(5.61, CI: 4.92, 6.29) and a 1% decrease (Mean: 5.74, CI: 5.22, 6.25). Avoiding hypoglycemia 
during the day only or avoiding 2 pills only was not valued significantly.  






Preference estimates for different attribute levels (n=552). Relative-importance estimates 
for attributes were rescaled relative to 10, corresponding to the absolute value of the 
most important outcome—90 minutes of nausea. The bar chart indicates the mean 
preference estimates. The short, bracketed, black vertical bars around the mean preference 
estimate indicate the 95% CI for the estimates (using SE). The box and whiskers plots 
indicate the 95% CI of the distribution of the preference estimates (using SD) around the 
mean. It indicates the spread in preference estimates (the level of preference 
heterogeneity) in the population. Within each attribute the vertical distance between mean 
estimates indicates the relative change in preference estimate for one level of the attribute 
compared to an adjacent level of the same attribute. 
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The probability that a treatment profile was chosen from a profile pair was 33% higher if the 
treatment decreased A1c by 1% compared to a treatment that did not decrease A1c. Treatment 
choice probability increased by 28% if the treatment offered stable blood glucose 6 days/week as 
opposed to 2 days/week. If a treatment profile caused 90 minutes of nausea a day instead of no 
nausea, the profile was 54% less likely to be chosen. A one-dollar increase in out-of-pocket cost 
was associated with a 1% decrease in the probability the treatment was chosen (Table 4-3). 
 
Discussion 
Our results are consistent with the idea that patients have strong preferences for immediate 
consequences of medication and discount future consequences of uncontrolled conditions.
69
 To 
accept 90 minutes of nausea a day, A1c levels had to decrease by 1% and blood glucose needed 
to be stable 4 days a week. Adherence for medications with significant side effects can be 
expected to be low, even if they are clinically effective.
70
 
We conducted preliminary conditional logit analyses to examine preference heterogeneity among 
people with different clinical backgrounds. No significant differences in preference estimates 
were shown between persons that had or had not experienced hypoglycemic events in the past 6 
months, except for taking 1 pill and/or 1 injection a day. Participants that were taking an injection 
as part of their treatment regimen had less pronounced differences for treatment burden than 
participants that only took oral medication (Appendix C).  
There is a rich and growing literature exploring the treatment preferences of patients with type 2 
diabetes using stated-preference methods.
16-18,71
 However, there is a paucity of studies that have 
been able to transparently describe the full research process
16,17
 given common publication word 
limits. In a systematic review on treatment preferences for diabetes only 5 out of 12 studies met 




Table 4-3 Results of mixed logit analysis 
 
  Preference estimates 
Change in choice 
probability 
A1c level decrease  Coefficient 95% CI  
1% 
Mean 5.74 (5.22, 6.25) 33% 
SD 2.88 (2.30, 3.46)  
0.50% 
Mean 5.61 (4.92, 6.29) 31% 
SD 5.45 (4.73, 6.17)  
0% 
Mean 0.00 (-0.51, 0.51) ref 
SD 2.57 (1.91,3.22)  




Mean 4.63 (4.15, 5.12) 28% 
SD 0.00 (-1.62, 1.63)  
4 days/wk 
Mean 3.52 (2.94, 4.10) 20% 
SD 2.47 (0.48, 4.46)  
2 days/wk 
Mean 0.00 (-0.46, 0.46) ref 





Mean 0.00 (-0.47, 0.47) ref 
SD 1.27 (0.42, 2.13)  
During the day 
Mean -0.48 (-1.07, 0.11) -3% 
SD 2.26 (0.28, 4.23)  
During the day and/or at night 
Mean -3.87 (-4.32, -3.42) -24% 





Mean 0.00 (-0.58, 0.58) ref 
SD 3.05 (2.44, 3.66)  
30 minutes/day 
Mean -2.78 (-3.34, -2.23) -15% 
SD 5.88 (5.12, 6.65)  
90 minutes/day 
Mean -10.00 (-10.53, -9.47) -54% 
SD 2.83 (2.21, 3.45)  




Mean 0.00 (-0.51, 0.51) ref 
SD 2.39 (1.75, 3.03)  
2 pills/day 
Mean 0.21 (-0.54, 0.97) 1% 
SD 6.68 (5.28, 8.08)  
1 pill and 1 injection/day 
Mean -7.04 (-7.63, -6.45) -39% 
SD 4.29 (3.68, 4.90)  
Out-of-pocket cost  
  
 
$1 increase Mean -0.14 (-0.17, -0.12) -1% 
Relative-importance estimates for attributes were rescaled relative to 10, corresponding to the absolute 
value of the most important outcome—90 minutes of nausea. Mean refers to the estimated mean 
preference estimate, SD refers to the standard deviation of the distribution around the mean preference 
estimate and is a measure of preference heterogeneity, the confidence intervals (CI) around the Mean and 




Despite differences in reporting transparency, the results of 17 diabetes DCEs are similar to the 
results from this study.
28
 It remains important to transparently discuss each step of the research 
process to ensure reproducibility. While results across studies might be similar, if methods are not 
clearly described, implications for clinical practice or for benefit-risk assessment might be 
limited. To remedy limited publication space, supplemental online appendices might provide an 
avenue for increasing reporting transparency. 
While this study attempted to follow good research practices, limitations exist. First, the Spanish 
version of the survey was not pretested although a native Spanish speaker checked the translation 
and initial responses to the Spanish survey were monitored. Generally survey translations should 
be pretested and pilot tested with native speakers. 56 out of 552 participants (10%) completed the 
Spanish version of the survey. Those who took the Spanish survey showed some differences in 
preference estimates (Appendix D), which could not be attributed to scale.
72
 





 and framing effect. 
21,77
 Randomizing the order of 
choice tasks for each participant minimized ordering effects but we could also have randomized 
the order of the attributes. Hypothetical bias was limited due to the inclusion of cheap talk and the 
use of a clinically relevant decision scenario. However, the lack of an opt-out option might have 
decreased the realistic nature of the choice tasks. While framing effects were limited because of 
extensive pretesting, by framing hypoglycemia as low blood glucose
78
 it might not have been 
perceived as harmful. A1c decrease and stable blood glucose might not have been understood 
clearly causing it to have an artificially low preference estimate.  
We attribute several positive outcomes in this study to the application of good research practices 
such as the low rates of attribute dominance, minimal participant burden, and the high level of 
choice stability and version equivalence. We recommend that researchers closely follow good 
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research practices and carefully consider limitations of stated-preference methods. While existing 
recommendations do not always detail which approach to take, by making deliberate decisions 
during study design choices can be justified.  
The Taskforce checklist 
The Taskforce checklist provides a useful tool for researchers to carefully consider each aspect of 
a stated-preference study. However, the checklist has limitations for use as a reporting template. 
First, some of the items do not have a clear place in study reporting. The statistical analysis item 
and results and conclusions item span the methods, results, and discussion section of a traditional 
manuscript, which makes it difficult to clearly report on them. The study presentation item cannot 
be summarized in one section but needs to be considered throughout the manuscript. Second, the 
requirement for “clear, concise, and complete” reporting is a paradox. We attempted to be 
comprehensive by including preference estimate distributions in Figure 4-2, but this might make 
it less clear to interpret. To be concise we did not conduct elaborate stratification analyses, which 
might reduce completeness of the study reporting. Third, the checklist is lengthy and certain 
aspects overlap. For example, questions around response burden appear both in experimental 
design and data collection. While these aspects should be considered at different points during the 
study, this can make following the checklist as a reporting template difficult. Other more concise 
reporting measures such as the PREFS
17
 checklist could be explored. 
Implications for good practices 
Despite numerous efforts to produce recommendations for the application of stated-preference 
methods, gaps on good research practices remain. Some of these gaps are presented in Table 4-4. 
Various methods, ranging from direct-assessment, threshold techniques, best-worst scaling, and 
DCE, require different approaches that are often not well differentiated. For example, it remains 
unclear which method is most appropriate for which research question or study population.  
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Table 4-4 Gaps in current guidance on stated-preference methods using the general 
framework 
Checklist item  Current gaps: 
1.Research question 
 What research questions can be answered by a stated-preference study? In what 
circumstances are other preference elicitation methods more appropriate? 
 What steps can be taken to ensure that the perspectives of multiple stakeholders 
are adequately represented in each phase of the study process? 
2. Attribute and levels 
 How can the negative effects of omitting attributes and positive effects of 
decreasing response burden be balanced?  
 What is the effect of including levels outside of the current clinical range in 
terms of respondents’ acceptance and in terms of extrapolating results?  
3. Construction of tasks 
 What is the effect of showing partial, instead of full profiles? How can results 
from partial profiles be appropriately combined?  
 Are there specific types of choice tasks that should be included in the 
instrument (e.g. a task with a dominated profile to test for rationality)? 
4. Experimental design 
 What are the effects of using an experimental design developed under different 
modeling assumptions than used for statistical analysis? 
 How can the tradeoffs between efficiency, orthogonality, level balance, and 
level overlap be balanced? 
5. Preference elicitation 
 What type of stated-preference method is most appropriate given the research 
question, study perspective, and proposed participants? 
 What types of evaluation questions on the preference-elicitation tasks should be 
asked? How do these evaluation questions affect confidence in preference 
results? 
6. Instrument design 
 What specific steps, such as pretest interviews or pilot testing, should be 
conducted for high quality instrument design? 
 What specific steps can be taken to  lower response burden, hypothetical bias, 
framing effects, and ordering effects? 
7. Data collection 
 What are sample size requirements for more complicated statistical models 
(such as mixed logit or latent class)? 
 How representative should the study sample be? How can representativeness be 
assessed (by demographic or disease history profiles, or preference profiles?) 
8. Statistical analysis 
 Which methods to analyze preference heterogeneity are most appropriate in 
which circumstance? What are limitations of each method? 
 What tests can be done to assess validity and reliability of stated-preference 
study? How many tests should a study meet for preference results be considered 
valid? 
9. Results and conclusions 
 What type of preference results (e.g. preference estimates, predicted 
probabilities, odds ratios) and uncertainty measures (e.g. p-values, standard 
errors) should be reported?  
 What are preferred terms to describe preference research and results? What are 
appropriate ways to test for and report preference heterogeneity? 
10. Study presentation 
 What steps should be taken to ensure uniform reporting standards of stated-
preference studies? How can transparency in stated-preference research be 
encouraged? 
 What steps can be taken to increase interpretability of preference results for 





With the increased use of complex experimental designs such as D-efficient
20
 or Bayesian 
designs, updated recommendations on experimental design would be valuable. Johnson et al. 
(2013) provide a comprehensive overview of the importance and the theoretical properties of 
experimental design. However, they give limited advice around practical considerations in trading 
off experimental design properties. Step-by-step recommendations on experimental design 
decisions would need to be supported by research such as the simulation approaches that have 
been used in transportation research.
79
 
Transparently reporting on study design, data analysis, and potential limitations will provide 
stakeholders with information to replicate and evaluate the study. Additional evidence on the tests 
that can be used to evaluate stated-preference data quality, such as rationality tests,
80
 or scope 
tests,
81
 needs to be collected to formally evaluate preference study quality.
2
 Eventually, 
standardization of tests to assess validity and reliability should be considered.  
Conclusion 
This study is explicit in the decisions that were made while conducting a stated-preference study 
and can be used as a case study on applying and reporting on good research practices. Until more 
research is done comparing different research practices, recommendations on conducting stated-
preference studies will remain opinion based. As various judgments need to be made when 
conducting stated-preference studies, these decisions should be carefully considered and 




Appendix C – selections of the diabetes treatment preferences survey 
 
SURVEY ELIGIBILITY QUESTION 
 
1. Have you been diagnosed by a doctor or other qualified medical professional with Type 2 diabetes? 
o Yes 
o No 
o Not sure  
 
Understanding your medication preferences 
 
The purpose of this section is to assess your preferences for diabetes medicines. Specifically, we ask that you consider 
the following situation.  
 
Suppose that your doctor says that your current diabetes medicine is not working to keep your blood sugar 
controlled. Your doctor recommends that you add another diabetes medicine to change your A1c.  
 
You will be shown a number of potential medicines that vary across several characteristics. These include the effect on 
your A1c levels, blood sugar stability, low blood sugar events, nausea, how it is taken, and its cost.  
 
The medicines will be exactly the same, except for the characteristics we show you. For example, you will not need to 
change how often you check your blood sugar levels (with for example a finger stick). 
 
These medicines do not actually exist, but answer as if they are real. First, let’s have a look at the characteristics of the 
medicine. 
 
A1c levels  
Doctors prescribe diabetes medicines to help lower your A1c, or average blood sugar level during the past three months. 
Keeping your A1c at the recommended level may decrease your risk for serious health problems such as heart attack, 
blindness, amputation, and kidney failure. When taking the new medicine your A1c level might go down by: 
  
 1% – this is a large decrease 
 0.5% – this is a moderate decrease 
 0% – this is no decrease 
2. How important is lowering your A1c? 
o Not important at all 
o Slightly important 
o Somewhat important 
o Important 
o Very important 
 
Stable blood glucose levels 
The new medicine might help keep your blood glucose levels stable on a daily basis. Your blood glucose levels are stable 
for the day if they stay in a range of 70-180 mg/dl. When taking this new medicine your blood glucose levels might be 
stable for: 
 
 6 days per week 
 4 days per week 
 2 days per week 
3. How important is having stable blood glucose levels? 
o Not important at all  
o Slightly important 
o Somewhat important 
o Important 
o Very important 
 
Low blood glucose 
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You might experience low blood glucose, also known as hypoglycemia. This may make you feel shaky/drowsy and have 
blurred vision or difficulty walking/talking. You might pass out (if you don’t eat or drink). Low blood glucose can also 
happen at night while you sleep. Then you won’t know about it and you might be more likely to pass out. You might 
experience low blood glucose: 
 
 None 
 During the day only 
 During the day and/or at night 
 
4. How important is avoiding low blood glucose events? 
o Not important at all  
o Slightly important  
o Somewhat important 
o Important 
o Very important 
 
Nausea  
The new medicine may cause moderate nausea. This means you feel sick to your stomach and like you need to vomit. 
When taking this new medicine you might experience nausea for a total of: 
 None 
 30 minutes per day 
 90 minutes per day 
 
5. How important is avoiding nausea? 
o Not important at all 
o Slightly important  
o Somewhat important  
o Important 
o Very important 
 
Treatment burden 
You will have to take the new medicine daily. You need to take this medicine in addition to the medicines you already 
take. We will consider three different ways of taking the medicine. You might have to take an additional: 
 1 pill per day 
 2 pills per day 
 1 pill and 1 injection per day 
6. How important is minimizing treatment burden? 
o Not important at all  
o Slightly important  
o Somewhat important 
o Important 
o Very important 
Medication costs 
The medicine will require out-of-pocket costs in addition to what you already pay for other medicines.  The money you 
spend on this medicine cannot be spent on other things. Your additional costs might be: 
 $10 per month 
 $30 per month 
 $50 per month 
1. How important is cost to you? 
o Not important at all 
o Slightly important 
o Somewhat important  
o Important 




Discrete Choice Experiment 
 
Consider the following two diabetes medicines. Which medicine would you prefer?   
 





Tom took the survey and was shown the following two medicines. He prefers Medicine B over Medicine A. 
 
Attributes Medicine A Medicine B 
A1c levels go down by 1%  0.5%  
Stable blood glucose 2 days per week  4 days per week 
Low blood glucose During the day None 
Nausea None 90 minutes per day 
Additional medicine  2 pills per day 1 pill per day 
Additional out-of-pocket costs  $50 per month $10 per month 
Which medication would you choose? 
(pick one) 
I would choose 
Medicine A 
☐ 





Task 8 – 25 Which medicine would you prefer?   
 
Attributes Medicine A Medicine B 
A1c levels go down by 0.5%  0%  
Stable blood glucose 4 days per week  6 days per week 
Low blood glucose During the day and/or at night During the day 
Nausea None 30 minutes per day 
Additional medicine  2 pills per day 1 pill and 1 injection per day 
Additional out-of-pocket costs  $50 per month $30 per month 
Which medication would you 
choose? (pick one) 
I would choose 
Medicine A 
☐ 




(18 questions of a similar format but with different levels. Participant were randomly assigned to one of three version 
blocks) 
 
[Displayed after question 9] 
 
Make sure that you consider all six characteristics of both medicines in your answers. You are halfway done with this part 
of the survey! Please keep going! Your answers are important to our research. 
 
Evaluation questions 
The following statements refer to the questions that asked about the diabetes medicines. Please indicate if you agree or 
disagree with the statements in the grid below. 
 











1 2 3 4 5 
I found it easy to 
understand the questions 
☐ ☐ ☐ ☐ ☐ 
I found it easy to answer 
all the questions 
☐ ☐ ☐ ☐ ☐ 
I answered all questions 
in a way consistent with 
my preferences 











Appendix D – Stratified conditional logit analyses  
Preference estimates  for stratified sample based on having experience a hypoglycemic event in the past 6 months 
  No hypoglycemic event  At least one hypoglycemic event    
  Coefficient SE Coefficient SE p 
A1c decrease 1.00% -6.20 0.43 -5.16 0.43 0.64 
0.05% -6.64 0.43 -4.51 0.38 0.15 
0.00% 0.00 0.41 0.00 0.40 0.36 
Stable blood 
glucose 
6 dy/wk -4.85 0.41 -5.00 0.35 0.44 
4 dy/wk -3.51 0.41 -3.55 0.38 0.89 
2 dy/wk 0.00 0.38 0.00 0.37 0.38 
Low blood 
glucose 
None 0.00 0.34 0.00 0.31 0.50 
Day 0.41 0.39 0.65 0.35 0.99 
Day/night 3.94 0.33 4.00 0.32 0.50 
Nausea None 0.00 0.46 0.00 0.46 0.21 
30 min 2.39 0.32 3.03 0.28 0.63 
90 min 10.00 0.46 10.00 0.42 0.33 
Treatment 
burden 
1 pill 0.00 0.43 0.00 0.41 0.22 
2 pills -0.28 0.51 -0.20 0.45 0.25 
1 pill + 1 inj 8.37 0.46 5.18 0.39 0.01* 
Cost $1 0.14 0.02 0.12 0.02 0.44 
 Wald test chi2( 11) =   16.74    
  Prob > chi2 =    0.1158    
 
Preference estimates for stratified sample based on medication use 
  No injection Injection   
  Coefficient SE Coefficient SE p 
A1c decrease 1.00% -5.22 0.37 -6.67 0.54 0.06 
0.05% -5.51 0.37 -5.51 0.44 0.68 
0.00% 0.00 0.36 0.00 0.46 0.08 
Stable blood 
glucose 
6 dy/wk -5.40 0.33 -4.22 0.46 0.82 
4 dy/wk -3.88 0.41 -2.81 0.49 0.72 
2 dy/wk 0.00 0.33 0.00 0.45 0.53 
Low blood 
glucose 
None 0.00 0.29 0.00 0.38 0.23 
Day 0.38 0.37 0.95 0.45 0.90 
Day/night 3.81 0.29 4.31 0.38 0.29 
Nausea None 0.00 0.40 0.00 0.56 0.22 
30 min 2.48 0.44 3.23 0.32 0.58 
90 min 10.00 0.38 10.00 0.55 0.41 
Treatment 
burden 
1 pill 0.00 0.37 0.00 0.46 <.001* 
2 pills -0.35 0.42 0.06 0.55 <.001* 
1 pill + 1 inj 9.50 0.40 1.41 0.35 <.001* 
Cost $1 0.13 0.02 0.11 0.03 0.40 
 Wald test chi2( 11) =   16.74    
  Prob > chi2 =    0.1158    
 
Preference estimates  for stratified sample based on survey language 
  English survey Spanish Survey   
  Coefficient SE Coefficient SE p 
A1c decrease 1.00% -5.75 0.31 -5.30 1.78 0.09 
0.05% -5.64 0.30 -6.58 1.81 0.37 
0.00% 0.00 0.29 0.00 1.54 0.0029* 
Stable blood 
glucose 
6 dy/wk -4.27 0.26 -18.13 2.16 0.0296* 
4 dy/wk -3.31 0.26 -9.26 1.63 0.32 
2 dy/wk 0.00 0.25 0.00 2.14 0.16 
Low blood 
glucose 
None 0.00 0.23 0.00 1.56 0.69 
Day 0.40 0.30 1.11 1.85 0.68 
Day/night 3.80 0.23 6.90 1.59 0.38 
Nausea None 0.00 0.33 0.00 1.85 0.0035* 
30 min 2.75 0.25 2.63 1.66 0.26 
90 min 10.00 0.31 10.00 1.65 <.001* 
Treatment 
burden 
1 pill 0.00 0.30 0.00 1.87 0.79 
2 pills -0.57 0.32 4.43 2.07 0.02 
1 pill + 1 inj 6.52 0.30 11.29 2.05 0.03* 
Cost $1 0.12 0.02 0.28 0.12 0.23 
 Wald test chi2( 11) =   16.74    
  Prob > chi2 =    0.1158    
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Purpose: Diabetes is a chronic condition that is more prevalent among people with lower 
educational attainment. We sought to assess the impact of educational attainment on treatment 
preferences of patients with type 2 diabetes.  
Methods: A diverse sample of patients with type 2 diabetes was recruited from a national online 
panel in the United States. Treatment preferences were assessed using a discrete-choice 
experiment (DCE). Participants completed 16 choice tasks in which they compared pairs of 
treatment profiles composed of 6 attributes: A1C decrease, stable blood glucose, low blood 
glucose, nausea, treatment burden, and out-of-pocket cost. We estimated choice models using 
conditional logit analysis and calculated willingness-to-pay (WTP) estimates stratified by 
educational status.  
Results: 231 participants with high school or less, 156 participants with some college, and 165 
participants with a college degree or more completed the survey. Participants with college or 
more were willing to pay more for A1C decreases ($58.84, SE: 10.6) than participants who had 
completed some college ($28.47, SE: 5.53) or high school or less ($17.56, SE: 3.55) (p<=.01). In 
addition, people with a college education were willing to pay more than people with high school 
or less to avoid nausea, low blood glucose events during the day/night, or 2 pills per day. 
Conclusion: WTP for aspects of diabetes medication differed for people with a college education 
or more and a high school education or less. A thorough understanding of preference 
heterogeneity across different subgroups can be used in patient-centered benefit-risk assessments 




Diabetes is a chronic disease that affects 29.1 million people (9.3%) and is the seventh leading 
cause of death in the United States (US).
1
 In 2012 in the US, 1.7 million people 20 years or older 
(or 7.8 per 1000 people) were newly diagnosed with diabetes and thirty-three percent of people in 
the US will develop type 2 diabetes during their life time.
1
 Diabetes related complications result 
in significant morbidity and costs
2
 and are associated with a reduced quality of life compared to 
the general population.
3
 While the prevalence of diabetes has gone up over time among all 




Treatment of type 2 diabetes most often requires a combination of lifestyle adaptation and 
medication. There exist multiple types of glucose lowering medication: oral medications, non-
insulin injections, and insulin.
5-8
 These treatments are associated with a range of side effects, 
including weight and blood pressure changes, gastrointestinal side effects, and cardiovascular 
risk. 
5,6,8
 Treatment guidelines emphasize the need to achieve treatment goals, including achieving 




Treatment outcomes for diabetes have been shown to improve when patients are involved in the 
treatment decision.
12
 Despite the high need for self-management in type 2 diabetes, much clinical 
research and care continues to neglect the patient perspective
13
 resulting in  low rates of 
medication adherence
14
 and low rates of achieving treatment goals.
15
 When incorporating the 
patient perspective, the effects of patient characteristics, such as educational attainment, on their 
treatment preferences should be considered. Not only are people with lower educational 
attainment more likely to develop diabetes, 
16-18
 they are also more likely to suffer from 




  Efforts to deliver diabetes treatments may be more effective if tailored to 
individuals' preferences and educational background. 
This study evaluates treatment preferences of patients with different educational attainment by 
estimating their willingness-to-pay (WTP) for type 2 diabetes medications. We hypothesize that 
people with more education are willing to pay more for diabetes medication. Understanding 
treatment preferences and WTP of patients with different levels of educational attainment might 
aid in informing and targeting patient-centered policies, treatment, and education efforts. The 
study illustrates an increasingly important research method for the measurement of patient 
preference and quantifies the preferences of patients with type 2 diabetes across the benefits, 
risks, and treatment burden of anti-glycemic medications. 
Methods 
Discrete Choice Experiments (DCEs) are one of the most common form of stated-preference 
methods, and guidelines have emerged for utilizing them. 
24-26
 Our approach was consistent with 
existing guidelines and is summarized under four headings: conceptual model, creation of the 
choice tasks, survey respondents, and statistical analysis.  
In a DCE, it is assumed that the treatment profile (in this case diabetes medication) is defined by 
a variety of characteristics, or attributes that can exist at different levels. A respondent is 
presented with two or more distinct profiles and is asked to select the profile they prefer. Based 
on participants’ repeated choices the relative preferences for the different attributes and levels can 
be estimated.  
Conceptual model 
The association between educational attainment and health outcomes is well known.
27-29
  In 
addition to life expectancy,
30




 Individuals with lower income and less education are 2 to 4 times 
more likely to develop diabetes
16
 and more likely to be affected by diabetes complications.
32
 In 
addition, treatments, such as intensive lifestyle interventions and metformin,
22
 can be more 
effective in people with higher educational attainment resulting in improved health outcomes.  
The association between education and health outcomes can be explained in four ways.
33
 First, 
schooling increases the efficiency with which health is produced.
34
 Second, schooling may affect 
how quickly people can obtain and process information.
35
 Third, schooling might teach people 
how to following instructions.
36,37




In the reverse association, health outcomes might influence educational attainment; people with 
poor health outcomes might have lower levels of education.
39-41
 This association is less likely to 
hold in the case of type 2 diabetes because type 2 diabetes is generally diagnosed later in 
adulthood when education has been completed.
42,43
 
The education-health association might be mediated by treatment preferences (Figure 5-1). 
Educational attainment can affect treatment preferences
44,45
 and preference stability.
46
 
Furthermore, patient’s preferences might affect health outcomes. When patients’ preferences are 
accommodated, greater adherence to therapy
47
 or feelings of control and greater health-related 
quality of life might results.
48
 In diabetes, time preference for the future are significantly related 
to diabetes complications.
32
 A link between patient preferences for treatment burden and 
adherence to diabetes medications has been shown.
49,50
 In addition, when physicians met their 
patients’ preferences for information, patients with type 2 diabetes attained better metabolic 




Figure 5-1 Conceptual model of relationship between educational attainment, preferences, 
and health outcomes 
 
 
The link between education and preferences in diabetes needs to be further explored. In a DCE on 
diabetes treatment, Guimaraes et al. (2009) found that income was related to treatment 
preferences, but they did not find this link between educational attainment and treatment 
preferences.
33
 However, a DCE published by Hauber et al. (2009) did find a difference in 
treatment preferences between people with some college education and no college education.
52
 In 
addition, educational attainment has been shown to influence people’s preferences for different 
types of diabetes self-management programs.
53,54
 This study will examine the link between 
educational attainment and treatment preferences for type 2 diabetes medication by estimating 
separate WTP models for people that completed high school or less education, that completed 
some college, and that completed college or more education.  
Creation of the choice tasks 
This DCE was developed using a rigorous engagement process that included synthesis of the 
existing evidence, expert consultations, stakeholder engagement, qualitative pretest interviews 
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(n=25), and quantitative pilot testing (n=27).
55
 The final instrument contained six attributes: A1C 
decrease (0%, 0.5%, 1% decrease), stable blood glucose (2 days/week, 4 days/week, 6 
days/week), low blood glucose/hypoglycemia (none, during the day, during the day and/or at 
night), nausea (none, 30 minutes/day 90 minutes/day), treatment burden (1 pill/day, 2 pills/day, 1 
pill and 1 injection/day), out-of-pocket costs ($10/month, $30/month, $50/month). The survey 
included detailed descriptions on all attributes and levels as well as an explanation and example 
on how to complete a choice task.  
With six attributes at three levels each, we could generate 729 distinct treatment profiles and 
more than 500,000 paired profile choice tasks. We selected a subset of these possible choice task 
using specialized software (Ngene, Choice Metrics)
56
 to create a D-efficient experimental design 
that took into account prior preference results from a pilot test. Respondents were randomly 
assigned to one of three survey versions that each contained 16 choice tasks. A sample choice 
task is presented in Figure 5-2. 






We stratified the model by educational status; we estimated separate choice models for 
participants that had completed high school or less education, participants that had completed 
some college, and participants that had a college degree or more education. We analyzed the data 
in Stata 13 (College Station, TX) using a conditional logit model.
57
 WTP estimates were 
calculated by taking the coefficient of each attribute level and dividing by the coefficient for cost: 




Standard errors were estimated using the delta method. Paired t-tests were used to test for the 
equivalence of individual coefficients between educational groups. We conducted a Swait-
Louviere scale test
58
 to test for differences in error variance between the model (Appendix). 
Survey respondents 
Members of a nationally representative online panel with type 2 diabetes were invited by email to 
participate in the survey (GfK KnowledgePanel). All participants were required to be 18 years or 
older with a self-reported physician-diagnosed type 2 diabetes and able to read English or 
Spanish. African Americans and Latinos were oversampled to account for the high prevalence of 
diabetes in these population.
59,60
 Survey participants received compensation from the online panel 
equivalent to about $10. The Johns Hopkins School of Public Health IRB determined this study 





552 people (66% response rate). Our participants were more likely to take medication and were 
living with diabetes longer than a 2011 national sample.
61,62
 231 participants had completed High 
School or less education, 156 participants had completed at least some college, and 165 people 
had completed college or more education (Table 5-1). Participants with more education were 
more likely to be male, were more likely to report better health status, and had higher incomes. 
There were no differences in years since diabetes diagnosis, having had a hypoglycemic events in 
the past 6 months, A1C levels, or medication use.  
WTP Results 
Table 5-2 presents WTP results stratified by educational attainment. Participants with high school 
education or less and participants with some college were willing to pay the most to avoid having 
to take 1 pill and 1 injection a day (WTP for high school or less: $-30.54, SE: 4.11; WTP for 
some college: $-38.25, SE: 6.10). They were willing to pay the least to avoid having to take 2 
pills a day (WTP for high school or less: $-5.22, SE: 2.89; WTP for some college: $-5.50, SE: 
3.43). Participants with a college degree or more were willing to pay the most for a 1% decrease 
in A1C (WTP: $58.84, SE: 10.60). They were willing to pay least to avoid low blood glucose 
events during the day (WTP: $-9.41, SE: 4.73).  
Participants with college or more were willing to pay more for A1C decrease ($58.84, SE: 10.6) 
than participants who had completed some college ($28.47, SE: 5.53) or participants who had 
completed high school or less ($17.56, SE: 3.55) (p<=.01). People with a college degree or more 
were also willing to pay more to avoid 30 minutes of nausea, low blood glucose events during the 
day and/or at night, and to avoid 2 pills a day. Other differences in WTP between educational 
groups were not statistically significant. 
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Table 5-2 Willingness to pay for diabetes medication 
 
   HS diploma or 




more (N=165) pHS=SC pSC=CO pHS=CO 

















1% 17.56 3.55 28.47 5.53 58.84 10.60 0.08 0.01* <0.01* 
Stable 
glucose 
4 dy/wk 23.12 3.88 29.82 5.06 35.00 8.17 0.29 0.59 0.15 




None 0 (ref) 0 (ref) 0 (ref)    
Day -10.27 2.47 -9.46 3.49 -9.41 4.73 0.85 0.99 0.09 





1 pill/dy 0 (ref) 0 (ref) 0 (ref)    
2 pills/dy -5.22 2.89 -5.50 3.43 -16.22 4.47 0.95 0.06 0.03* 
1 pill + 1 
inj/dy 




= Willingness to pay; 
b
SE = standard error, 
c
 t-test for equivalence between WTP of educational 
groups; *significant at the .05 level
 
 
Figure 5-3 presents how people in different educational groups would allocate $100 dollars 
between the different aspects of diabetes medication. This budget allocation was done to examine 
the priorities of the different educational groups under equal budgets. It only considered the most 
extreme levels for the categorical attributes (nausea, low blood glucose, and 1 pill + 1 injection) 
to avoid doubling up between attributes.  
The biggest differences between educational groups could be seen in allocation for A1C decrease, 
followed by 1 pill and 1 injection a day. People with a college education or more would allocate 
$30 for a 1% decrease in A1C, while people with some college would pay $21, and people with 
high school or less would pay $17. In addition, people with some college or less education were 
willing to pay more for 4 days of stable blood glucose a week than for a 1% decrease in A1c. 
People with a college education or more would allocate $24 to avoid 1 pill and 1 injection a day, 
while people with some college would pay $28, and people with high school or less would pay 
$30. All groups would be willing to pay the least ($13-14) to avoid 30 minutes of nausea a day.   
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DCE provides researchers with a theoretically grounded method for the study of preferences.
25,26
 
Stated-preference methods are particularly valuable in the healthcare realm because we often we 
cannot observe people’s real world choices when medications are in development or are not yet 
approved. We conducted a DCE to assess WTP in patients with type 2 diabetes for diabetes 
medication. We showed that patients with type 2 diabetes do not only value reductions in their 
A1C levels, but also had preferences for medications that stabilized their daily glucose levels and 
that reduced burden/harms of medication.  
We found that patients with different educational attainment displayed different preferences for 
diabetes treatment. In particular we found that patients with a higher education were willing to 
pay more for all medication attributes than patients with lower educational attainment. For 
example, patients with a high school diploma or less education were willing to pay less than half 
for a 1% reduction in A1C than participants with college or more. In addition, patients with a 
college degree or more were willing to allocate the most of their budget to A1C decrease, while 
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patients with some college or less education allocate most of their budget to avoiding 1 pill and 1 
injection per day. We also found that people with some college or less education were willing to 
allocate more for 4 days of stable blood glucose a week than for a 1% decrease in A1c. 
This study has several limitations. First, weight was not included as an attribute based on our 
instrument development process. This decision was partly made because weight gain could be 
interpreted as either positive or negative depending on the person and their current weight. While 
it is generally assumed that patients with type 2 diabetes would benefit from weight loss, this 
does not apply to some elderly, frail patients. To avoid estimation ambiguities that could arise due 
to this issue, and after consulting with diabetes experts and patients with diabetes we decided to 
not include weight changes as an attribute. Unless weight changes were dependent on one of the 
included attributes, this should not have affected the estimated importance of each attribute. 
Second, a previous study found that people with lower educational attainment were less 
consistent in the choices they made in a DCE.
63
 If participants do not understand the choice tasks 
or attributes, they might be less consistent in the choices they make and their estimated preference 
weights are biased towards the null. In our results, we observed that people with a lower 
education are willing to pay less for every medication attribute. However, participants with lower 
educational attainment did not report that they had more difficulty with answering the choice 
tasks consistently. In addition, participants with lower educational attainment did not report more 
difficulty with understanding and/or answering the choice tasks. This suggests that their lower 
willingness to pay might not be due to lower choice consistency or lack of understanding.  
Finally, to maintain sufficient power, the analyses could not be controlled for other variables such 
as race, or income. Therefore it is not clear whether observed differences in preferences were due 
to educational differences or other differences in the groups. We did conduct a stratified analysis 
by income, which showed that between two income groups (below $50,000 and above $50,000 a 
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year) WTP differed only on A1C decrease and avoiding 1 pill + 1 injection per day (Appendix). 
Segmentation techniques using finite mixture models
64,65
 might be more appropriate to detect 
subgroup heterogeneity. These techniques group individuals based on the preferences they 
displayed. The characteristics of people that make up these preference-based groups can then be 
observed to detect multiple factors that are predictive of preferences.  
Stratification approaches present a way to analyze preference heterogeneity based on predefined 
subgroups, but are limited by the number of subgroups that can be examined. Other analytical 
techniques might be able to predict factors that influence preferences. A thorough understanding 
of preference heterogeneity can be used in patient-centered benefit-risk assessments and 
personalized care approaches.  
Conclusion 
The findings of this study help clarify what aspects of diabetes medication are important to 
patients and describe differences in WTP of patients with different educational attainment. Our 
results suggest that patients with lower levels of education might be more bothered by treatment 
burden. In addition, we found that people with lower educational attainment might place more 
value on keeping their glucose levels within a daily target range rather than maintaining 
controlled A1c levels. Being aware of patient preferences and how these preferences are 
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CHAPTER SIX  
-  
ASSESSING THE VALIDITY AND RELIABILITY OF APPLICATIONS 
OF DISCRETE-CHOICE EXPERIMENTS IN HEALTHCARE 




While discrete-choice experiments (DCE) and other stated-preference methods are now routinely 
applied in healthcare, their recent acceptance by regulatory and health technology assessment 
(HTA) agencies have placed a greater focus on demonstrating validity and reliability of 
preference results. Based on a targeted literature review, we identify a variety of methods to test 
for validity and/or reliability of DCEs. We identify four domains for the validity of a DCE: 
measurement validity, preference reliability, decision processes, and choice rationality. These 
domains consist of 14 components that can be identified using 24 possible tests of validity and 
reliability. We discuss each test and direct readers to applications of these tests in the healthcare 
DCE literature. We discuss study design considerations that need to be made to test for the 
validity and reliability of a DCE and consider limitations to the current application of validity 
tests for DCEs in healthcare.  
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Introduction.  





 and regulatory decision making.
4,5
 As regulatory and health technology assessment 
decision making
6,7
 is becoming more patient-centered, ways to measure preferences of health care 
stakeholders are being explored.
8
  Patient preferences play an important role in many quantitative 
approaches to benefit-risk assessment
9
 and stated-preference methods, such as discrete-choice 
experiments (DCEs) are increasingly used to study benefit-risk.
10
 A growing number of HTA 
agencies are now formally incorporating patient preferences into their decision making.
6,11,12
 The 
United States (US) Food and Drug Administration (FDA) has already provided guidance on 
quantitative preference assessment for medical devices.
13
 
To be able to fully incorporate patient-preference information in healthcare decision making 
processes, preference studies will need meet evidence standards consistent with standards for 
clinical evidence.
8
 Guidance from the United States Food and Drug Administration on 
incorporating patient preference information in benefit-risk assessments calls for checks on the 
quality of stated-preference studies,
13
 including the logical soundness and validity of a patient 
preference results.  However, validating stated-preference assessments is difficult due to the 
hypothetical nature of the choices participants make.
14
 Therefore, it is unknown whether patients 
would display the same preferences if they would experience the consequences of their choices.  
Validity of stated-preference methods when compared to revealed preferences has been explored 
in transport, marketing, and environmental economics.
15,16
 Opportunities to observe preferences 
through real-life choices in healthcare are be limited
10
 because healthcare options might not be 
available on the market yet,
13
 or choices are made on behalf of the patient by a physician
17
 or a 
third-party payer.
18,19
 A recent systematic review in the application of DCEs in environmental 
economics found that environmental DCEs generally provide limited evidence on the internal 
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reliability and validity of DCEs.
20
  The Medical Device Innovation Consortium (MDIC) has 
called for studies that evaluate specific aspects of the validity of DCEs that are applied to 
healthcare.
8
 While literature reviews on the application of DCEs in healthcare have discussed 
tests of internal validity, the tests discussed in these reviews has not been comprehensive.
21-23
 
Furthermore, these discussions often do not provide details on how to conduct tests for validity 
and reliability.  
The MDIC report defines validity of a stated-preference study as “the extent to which quantitative 
measures of relative importance or tradeoffs reflect the true preferences of patients.”
24
 We used 
this definition to identify specific tests in the DCE literature in healthcare that might assess the 
validity and reliability of a discrete-choice study. We conceptualize the validity and reliability of 
a DCE into four domains. Then we compile a comprehensive list of tests of validity and 
reliability applied in the healthcare DCE literature. Furthermore, we explain how these tests can 
be conducted and refer readers to applications in the healthcare literature. We then discuss 
considerations that need to be taken into account when designing a DCE to allow for tests of 
validity and reliability. This review can help researchers identify and apply tests into their studies 
that can be used to examine the validity of their results.  
Methods 
We conducted a targeted literature review to identify articles that discussed validity of DCEs. We 
were only interested in tests of validity and reliability that were mentioned in the DCE literature 
in healthcare. We searched PubMed Central for stated-preference studies that used the word 
validity and/or reliability and were published between January 2000 and January 2017. While we 
were only interested in DCEs, we included more general search terms related to stated-preference 
studies including “patient preference”, "stated preference”, "conjoint analysis”, and “choice 
experiment” to avoid excluding relevant studies. We also conducted a hand search to identify 
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studies that reviewed DCEs or that assessed the reliability or validity of a DCE but were omitted 
in the targeted search.   
We included papers that gave an overview of DCEs as a stated-preference method and discussed 
the theory and methods of DCEs and that mentioned ways to ensure validity or reliability of 
results. Select empirical papers were included to illustrate how tests of validity and reliability can 
be applied with examples from the literature. We excluded studies that did not discuss DCEs, or 
that did not discuss tests that could be done to evaluate the validity or reliability of a DCE. We 
also excluded studies that were not related to healthcare or that only employed qualitative 
methods. From the included literature we extracted tests of validity and reliability. We grouped 
tests into domains and components based on the concept of validity they addressed.  
Results 
Targeted Literature Search 
Using the PubMed search, we identified 139 studies. From the hand search, we identified an 
additional four articles. After title and abstract review, we excluded 109 studies. 42 studies went 
through full text review. Thirteen of these studies were reviews or made a methodological 
contribution in describing and applying a test (Table 6-1). Four were literature reviews,
21-23,25
 
three provided overviews on how to conduct stated-preference studies,
26-28
 and seven provided a 









Types of tests 
We identified four domains that define the validity and reliability of a DCE: Measurement 
validity, preference reliability, decision processes, and choice rationality (Figure 6-1). 
Measurement validity and preference reliability capture traditional measures of validity and 
reliability including how accurately the instrument measures preferences, how consistently it 
measures preferences, and the generalizability of these preference measurements.
35
 Decision 
processes and rationality of choice examine whether the results adhere to assumptions specific to 
random utility theory and consumer choice behavior.
36
 The four domains consist of 14 
components that can be examined through 24 identified tests. Below we discuss each domain and 
its components. The 24 identified tests are discussed as part of the component of validity that they 
assess. In Table 6-2 we present a summary of each test and provide a reference for an application 
of each test. 





• Level recoding 
• Task non-attendance 
• Monotonicity 
• Transitivity 
• Sen's consistency 
• Test-retest reliability 
• Test-retest stability 
• Version consistency 
• Prediction of choices 
• Face validity 
• Content validity 
• Convergent validity 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Measurement validity captures whether the results from a DCE meet face validity, content 
validity, convergent validity, and external validity. These concepts identify how accurately the 
instrument measures preferences and how generalizable these preferences are to other 
circumstance. 
Face validity 
Face validity, also referred to as theoretical validity, 
21,22,25,27
 assesses the extent to which the 
results are consistent with a priori expectations. We prefer the term face validity as theoretical 
validity can also refer to the axioms of consumer welfare theorem. 
28,33
 Face validity of results 
can be examined by setting a priori hypotheses for the preference relation between the attribute 
levels. For example, it can be expected that a high clinical benefit will be seen as more positive 
than a low benefit. This hypothesis can then be checked by looking at the direction of the 
preference estimates.
28,37
 Assessing face validity is a relatively simple test of validity; about 60% 
of DCEs published between 2009–2012 reported it. 
21
 
Ryan et al (2003) suggest that considering how results match “intuition” can assess face validity. 
For example, it might be expected that patients that have experience with an illness value 
treatment differently than the general public.
23
 We suggest that researchers use caution using this 
intuitive approach because there are many ways to establish preference heterogeneity.  
Content validity 
Content validity refers to the extent to which the DCE takes account of all things deemed 
important in the construct’s domain.
25
 In a DCE, this refers to the attributes and levels included in 
a study. While not every attribute that is important to every possible respondent needs to be 
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included, it is crucial to capture attributes important to a majority of participants.
26
 Content 
validity cannot easily be assessed through quantitative means. Rather it can be assessed by 
examining the instrument development process.
27,38
 for example whether experts were consulted 
and whether pretest or pilot tests were conducted.
34
 In addition, clinical experts and study 
participants can shed light on whether important attributes were omitted and whether the 




Convergent validity measures the extent to which the results from the DCE are consistent with 
other measures that are believed to measure the same construct.
25
 Preferences elicited for the 
same treatment from the same population are expected to be similar regardless the method used to 
elicit these preferences. Comparisons can be drawn between DCE, visual analog scale, and time-
trade off 
40
 or direct elicitation of WTP.
41
 Participants should either complete both types of 
instruments, or should be randomized to each instrument to minimize sample biases.  
Comparisons can also be drawn between different stated-preference studies in the same 
preference elicitation instrument. For example, Hollin et al. (2016) conducted a best-worst scaling 
experiment to measure treatment preferences. They included a choice based discrete choice 
question after each BWS task that asked whether participants would accept the treatment.
42
 
If resources are not available to conduct two types of experiments, researchers can compare 
preference estimates they obtain to those reported in the literature.
43,44
 In this case, care should be 
taken that preference estimates are appropriately compared: different studies might use different 
estimation methods and slightly different attributes. In these cases it can help to standardize these 





External validity, sometimes referred to as criterion validity, refers to the extent to which the 
preference results obtained from the instrument can be generalized to situations and people 
outside of the study. In stated-preference studies it is often described as the capability of a model 
to accurately predict preferences and choices outside of the immediate model context.
31
 For DCEs 
this is most easily examined by studying the choices people make in the real world, their revealed 
preferences, and comparing those to the preference estimated in the DCE.
34
 This can be done by 
jointly estimating revealed and stated preference estimates.
45
 In the healthcare sector, there have 
been relatively few studies that have examined external validity of DCEs,
21
 partially because 




Preference reliability captures whether the DCE produces similar results under consistent 
conditions. Preference reliability includes concepts of test-retest reliability, test-retest stability, 
version consistency, and predictive accuracy. It measures whether results can be reproduced or 
repeated over a given time. However, random utility theory, on which stated-preference methods 
are based, includes a random component. Therefore, reliability cannot be expected to be perfect.  
Test-retest reliability 
Test-retest reliability refers to the extent to which the instrument results in consistent preference 
estimates over time. This is tested by asking a sample of respondents to complete the same DCE 
twice at different times. The results are then compared with those from the first time the DCE was 
administered.
40
 Test-retest reliability can be examined by calculating the correlation coefficient 
(r) when using continuous variables and the Kappa coefficient (κ) when using categorical 
variables.
25
 Test-retest reliability can be problematic if a long period is allowed to pass between 
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the exercises, as people’s circumstances and preferences can change. In that case, the study 




Test–retest stability refers to the extent to which preferences are consistent for the duration of the 
survey.
33
 To test for test-retest stability, the same choice task needs to be presented to participants 
twice. The proportion of participants that answer this repeat-choice task the same way twice can 
then be established.
33
 A Kappa coefficient can also used to examine the difference in expected 
and observed consistency.  
Test-retest stability is different from test-retest reliability in that it measures choice consistency 
for only one choice task. Test-retest stability has the advantage that the instrument only needs to 
be administered once and that preferences are less likely to change over the course of single 
instrument than over the period between consecutive survey administrations. However, test-retest 
stability only measures consistency for a few (at minimum one) choice tasks and might therefore 
give a less accurate view on reliability of preferences. For example, if the repeat choice task is 
first presented at the beginning and then at the end of the instrument, learning effects or fatigue 
might affect the test-retest stability.
33
 In addition, the options presented in the repeat task might 
affect test-retest stability. For example, a task might include options that many people are 
indifferent to. This increases the probability that they choose a treatment profile almost randomly. 
In this case test-retest stability can be expected to be low, even if test-retest reliability for the 
entire instrument could still be relatively high.  
Version consistency 
Version consistency refers to the extent that different versions of the same DCE result in 
consistent preference estimates. In experimental designs in which different respondents see 
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different combinations of choice tasks, such as blocked or individualized designs, one or more 
hold-out of fixed choice tasks that are the same for each respondent can be included. 
27
 Responses 
to this hold-out task can then be compared across survey blocks 
44
 or across random splits in the 
sample using a simple t-test.
47
 The more hold-out tasks are included across the survey versions, 
the more accurately version consistency can be established. However, adding extra tasks to the 
experimental design decreases statistical efficiency and increases response burden.  
Another way to test version consistency is by making small changes to survey versions, by for 
example using labeled and unlabeled decision scenarios
37
 or in the framing of attributes.
48
 This 
approach has the disadvantage that by making changes to the survey a different preference 
construct might be measured and responses are not comparable. 
Predictive accuracy 
Predictive accuracy refers to the extent to which the choice model predicts choices outside the 
model but within the DCE.
27
 One or more choice tasks, holdout tasks or fixed tasks, which are not 
part of the experimental design of the DCE, can be included in the instrument. Then, preference 
estimates obtained from the choice tasks that are part of the experimental design can be used to 
predict the probability that each treatment profile in the additional choice task(s) is chosen.
49
 




Another method to test predictive validity is to take use multiple surveys. Preference estimates for 
one of the survey versions can be estimated and used to predict the choices for the other survey 
version.
51
 Muhlbacher and Johnson (2016) note that it may be easier to predict choices for one 





Decision processes  
Decision processes examine whether participants engage with the choice task in the intended 
manner and whether they are willing to accept trade-offs within the ranges of levels in the study 
design.
27
 It includes concept such as task non-attendance, level recoding, and compensatory 
preferences.  
Compensatory preferences 
Compensatory preferences refer to the extent that participants trade between all attributes of 
treatment profiles. DCEs assume that participants consider all attributes in their decision making 
and that there is always some improvement in one attribute that can make up for the reduction in 
another. Non-compensatory preferences can either be indicated by attribute dominance or 
attribute non-attendance.  
Generally, compensatory preferences have been tested by looking at attribute dominance.
28
 In 
attribute dominance choices are solely based on one attribute. Attribute dominance is present if a 




When attribute non-attendance is present, respondents make choices while ignoring one or more 
attributes. Attribute non-attendance can be examined through a multi-step latent class analysis 
approaches,
30
 Attribute non-attendance might be a more comprehensive approach to examining 
non-compensatory preferences in DCE,
30
 but is also more complicated to test. Lagarde (2013) 
argues that attribute dominance can also be conceptualized as attribute non-attendance because all 





Level recoding refers to the extent that participants process the actual the numbers presented in 
continuous or numeric attributes. Recoding may be a strategy for simplifying evaluations of a 
relatively unfamiliar but important attribute. Instead of interpreting the actual number and the 
numeric differences between attribute levels, participants might recode the levels to ‘low,’ 
‘medium,’ and ‘high’ categories.  
Recoding can be tested using a scope test, which involves creating two survey versions. For the 
numeric attribute, these two survey versions need to include some of the same levels (overlapping 
levels) and at least one different level so the level range is different for the two surveys. If 
preference estimates are the same for overlapping numeric levels between the two survey 
versions, we can infer that respondents did not recode the levels but rather reacted to the absolute 
levels. If the preference estimates for the overlapping levels are different, this suggest that 
participants recoded the numeric values as “high,” “medium,” or “low.” 
52
 
An approximation of the scope test, a simple scope test, can be done using just one survey version 
with a large difference and small difference between the levels of the numeric attribute included. 
If the difference in preference estimates between the large and the small level difference are 
similar, this might indicate that participants recoded the numeric levels as ‘low,’ ‘medium,’ and 
‘high’ 
29
. However, the simple scope test does not determine with certainty that recoding occurred 
because the preference function might not be linear. Figure 6-2 gives a graphical illustration of 
the full scope test and the simple scope test. 
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 Figure 6-2 Illustration of the Scope test and Simple Scope test to test for level recoding 
 
  
Panel a. Simple scope test. In this 
chart the cost attribute appeared at 
three levels $0, $3, and $10. The red 
line indicates no recoding took place. 
The blue line indicates recoding 
might have taken place – the 
difference in preference estimates 
between the small increase in cost 
($0-$3) is the same as the difference 
in preference estimates between the 
large increase in cost ($3-$10). 
However, this could also indicate 
diminishing marginal utility. 
 
Panel b and c. In these charts, two 
survey versions are represented. In 
version 1 the cost attribute appeared 
at $0, $3, $10. In version 2, the cost 
attribute appeared at $0, $, $6. 
 
Panel b. Scope test – no recoding. 
In this chart, the preference estimates 
for $0, $3 are the same for version 1 
and version 2. This indicates that 
participants traded based on the 
numerical values of the cost attribute. 
 
Panel c. Scope test – recoding. In 
this chart, the preference estimates 
for $0, $3 are different for version 1 
and version 2. This indicates that 
participants recoded attributes to 
“low”, “medium”, “high”. 
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Task non-attendance 
Task non-attendance refers to the extent that participants pay attention to the choice tasks. It is 
assumed that participants actively engage in the choice task, but if the task is too cognitively 
burdensome or not realistic, they might not carefully consider their decisions.
27
 Participants that 
always choose the treatment profile in a position in the choice task, for example the treatment 




Rational choices examine whether participants make choices in accordance with consumer choice 
theory. This theory assumes choices reflect completeness, reflexivity, transitivity, continuity, 
monotonicity or non-satiation, convexity, and Sen’s expansion and contraction principles.
22,33
 
Using DCEs we can measure whether choices adhered to monotonicity, transitivity, and Sen’s 
expansion and contraction principles  
Monotonicity 
Monotonicity, also referred to as non-satiation, means that people will prefer “better” levels of an 
attribute, or attributes that give them higher utility. Two types of monotonicity can be tested: 
within-set monotonicity and across-set monotonicity.
27,33
  
Within set monotonicity tests for non-satiation within a choice task. It can be tested by adding a 
dominant choice task to the instrument design. This means that for one of the treatment profiles in 
a choice task all the attribute levels are just as good as the attributes levels of the other profile and 
at least one attribute level is better.
28,32,33
 If uncertainty about how participants value certain 
attributes exists, these attributes should be held constant across the treatment profiles in the 
choice task. To satisfy the monotonicity requirement, a participant should choose the preferred 
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treatment profile. However, there in a two-profile case there is a 50% probability that someone 
that doesn’t pay attention to the choice tasks will pass the test for within-set monotonicity. 
33
   
Across-set monotonicity tests for non-satiation across choice tasks; it checks whether people 
choose the preferred treatment profile if one profile dominates another across choice tasks. For 
example, participants might choose treatment B over treatment A in one choice task. If all of 
treatment C’s attribute levels are better than for treatment B, they should also choose treatment C 
over treatment A in another choice task. Treatment profiles that can be used to test for cross-set 
monotonicity can occur spontaneously in an experimental design, especially if a constant opt-out 
or status-quo option is included.
33
 However, researchers might need to add one or more choice 
tasks to test for cross-set monotonicity.  
Transitivity 
Transitivity refers to the preference relation between three or more treatment profiles. In 
particular, if Treatment A is preferred to Treatment B in one choice task, and Treatment B is 
preferred to Treatment C in another choice task, then the transitive property states that Treatment 
A should be preferred to Treatment C in a third choice task. To test for transitivity, at least three 
related choice tasks need to be included in the DCE instrument. The first choice-task, the choice 
between Treatment A and Treatment B, can be part of the regular experimental design. The other 
two choice tasks (Treatment B v. C and Treatment A v. C) will most likely need to be added to 
the instrument outside of the existing experimental design. 
Sen’s consistency 
Sen’s consistency principles provide a more stringent test of rationality than the traditional 
monotonicity tests.
28
 Sen’s consistency principles 
55
 consist of both the contraction principle and 
the expansion principle. Sen’s contraction principle states that if a choice set A is narrowed (to B) 
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and some of the chosen from A are still in B, then no unchosen alternatives should be chosen now 
and no chosen alternatives should be unchosen now. Sen’s expansion principle states that if a 
choice set A is expanded (to C) and some of the chosen from A are still in C, then no unchosen 
alternatives from A should be chosen now. To test the contraction or expansion property, 
respondents should be presented with an initial choice task and a follow-on choice task.  
For the contraction principle, the initial choice task should contain at least three treatment choices 
(e.g. Treatment A, Treatment B, no treatment). The follow-on contraction choice task should 
present fewer choice tasks then the initial choice task (e.g. Treatment A, Treatment B). The 
contraction property is satisfied if a person that chose Treatment A in the initial choice task, still 
chooses Treatment A in the follow-on contraction choice task.
32
  
For the expansion principle, the first choice task should contain at least two treatment options 
(e.g., Treatment A, Treatment B). The follow-on expansion choice task should present more 
choice tasks then the initial choice task (e.g. Treatment A, Treatment B, no treatment). The 
expansion property is satisfied if a person that chose Treatment A in the initial choice task, does 
not chose Treatment B in the follow-on expansion choice task.
32
 
Study design considerations 
To be able to conduct many of the discussed validity tests, particular adaptations to the study 
design of a DCE need to be made (Table 6-2). These adaptations might increase study costs or 
might decrease statistical efficiency or increase response burden. Face validity, content validity, 
attribute dominance, and attribute non-attendance do not require special study design 
considerations so can be relatively easily incorporated into almost any DCE if the entire study 
process, including instrument development, is transparently reported. While attribute non-
attendance does not require special study design considerations, it does require the use of a 
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relatively complex analytical process. In addition, external validity does not require changes to 
the study design, but revealed preferences might not exist and/or might require complex statistical 
analyses. Therefore, these tests might be more difficult to conduct. 
To be able to test for monotonicity, transitivity, Sen’s consistency principles and test-retest 
reliability at least one additional choice task needs to be added to the study design. To be able to 
test for level recoding, different instrument versions need to be administered to different 
participants. To be able to test for test-retest reliability, the DCE needs to be administered twice 
to the same group of participants. Convergent validity can be tested by conducting a second 
choice experiment either as part of the DCE instrument or outside of it. Version consistency and 
prediction accuracy can be tested by either adding a fixed-choice or hold-out task or by 
administering multiple survey versions to different participants. 
In the cases where validity tests can be performed using multiple study design adaptation, the 
type of adaptation that requires more resources generally presents a more stringent test. For 
example, to test for level recoding, a scope test requires that different survey versions are 
administered to different participants. The simple scope test only requires the adaption of the 
numeric attribute levels, but this test is not conclusive whether recoding occurred or whether 
preferences are not linear. Generally, more stringent test for choice rationality require larger 
adaptations to the study design.
28
 Within-set monotonicity is regarded the weakest test of choice 
rationality because it can relatively easily be passed by chance.
33
 Testing for within-set 
monotonicity only requires one additional choice task. Transitivity and Sen’s consistency theory 
are more stringent tests of rationality but require larger changes to study design. Testing 
transitivity requires the addition of at least two choice tasks. Testing Sen’s consistency principle 
requires the addition of at least one choice task that doesn’t follow the format of the other choice 
tasks which might add complexity to the instrument.  
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Discussion 
While a variety of tests exist to assess the validity of a DCE, important questions remain. It is 
unclear what to do with participants that fail tests for validity or reliability.
28
 Excluding 
participants that fail the test for compensatory preferences or choice rationality might increase 
internal validity but will decrease external validity of results. Deleting responses can increase 
sample selection bias and increase the statistical efficiency and power of the estimated choice 
models.
56
 In addition, participants that fail these tests might have made their choices according to 
their actual preferences. Follow up questions or debriefing interviews could be shed light on the 
way participants answer choice tasks.
32
  
Furthermore, it remains unclear exactly when a test of validity or reliability is met. This is 
especially difficult for tests that require some qualitative or subjective assessment such as face or 
content validity. However, ambiguous requirements for more quantitative tests exist as well. For 
example, the acceptable frequency of dominant preferences, or failure rates of rationality tests or 
test-retest stability in a study are not well-established. It is also not clear what tests need to be met 
for a DCE study to be considered valid. It is unlikely that one study can incorporate each test of 
validity or reliability, especially because many tests require an adaptation to the study design.  
This study has several limitations. First, we conducted a targeted review of only one database that 
only spanned the past 10 years. Thus, certain articles discussing tests of validity and reliability 
might have been omitted. However, because most articles discussed similar tests of validity and 
reliability and because we supplemented our targeted literature search with a hand search, we are 
confident that we identified the most common tests.  
Second this study does not discuss the results of validity and reliability tests; it does not discuss 
whether DCEs published in the literature meet tests of validity and reliability, but discusses the 
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types of tests that could be performed. The purpose of this manuscript was to provide researchers 
with various tests they could consider when conducting or evaluating stated-preference studies. 
We did not want to conduct a study on the validity of published DCEs. 
Third, this study did not discuss Lanscar and Swait’s reconceptualization of external validity as a 
process rather than an outcome measure. Lanscar and Swait raise excellent points in how to 
ensure that the process of conducting a DCE supports external validity and suggest that this can 
be done by employing qualitative methods. Qualitative methods in the development and 
implementation of a DCE are also important to ensure content validity, face validity, and to 
examine rationality of choices.
56
 We chose not to discuss this conceptualization as it touches upon 





Due to the complexity of DCEs, most studies will neither include nor meet all tests of validity and 
reliability identified in this review. More studies should be conducted to investigate the 
determinants of DCE validity. A standard set of tests to be included in every DCE and cut-off 
points at which these tests are or are not met should be established. While limitations in 
establishing reliability and validity of a DCE remain, this study can help researchers gain insights 
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CHAPTER SEVEN  
-  
CONCLUSION AND POLICY IMPLICATIONS 
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Summary of findings 
This dissertation illuminates the mechanisms behind advancing good research practices and 
reporting conventions for preference research. It illustrates the cyclical and iterative process and 
the need to engage multiple stakeholders in the instrument development process. Furthermore, we 
conducted a subgroup analysis of preferences based on a conceptual model on the link between 
education, preferences, and health outcomes instead of a post-hoc analysis. This dissertation 
illustrates the importance of reporting study steps and decisions when conducting a stated-
preference study: all steps from instrument development to data analysis were carefully detailed 
and data driven to ensure transparency of research methods.  
We attribute several positive outcomes in this study to the application of good research practices. 
First, during the pretest, patients demonstrated that they understood the purpose of the study and 
thought it was important to measure preferences. Second. the rate of attribute dominance in the 
final survey was relatively low (16% vs. 40% in the pilot study) and participant burden seems to 
have been minimized. Thirds, the high level of choice stability and version equivalence point to 
the validity of the preference results. Other advantages of applying good research practices lie 
within the appropriateness of the mixed logit model that identified preference heterogeneity, and 
the face validity of the results. 
The dissertation has several limitations. First, it was based on consensus based good research 
practices and is therefore limited by existing methodological gaps as outlined in Chapter 4. 
Current recommendations are limited by the lack of evidence on good research practices. Until 
more research is done comparing different research practices, recommendations on conducting 
stated-preference studies will remain opinion based.  
Second, the approach of this dissertation was largely based on synthesis of published evidence. 
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While we involved patients with type 2 diabetes in the pretesting of the survey instrument, patient 
engagement was relatively limited. Our stakeholder committee was made up of a variety of 
clinical, methodological, and regulatory experts.  Engagement was mainly focused around clinical 
and methodological questions, not around gaining insight into patients and/or community 
experiences. Other stated-preference studies have placed much more focused on patient 




Third, while this work considered preference heterogeneity through the use of a mixed logit 
model and stratification analyses by education, more advanced methods to explore preference 
heterogeneity were not employed. While stratification models are useful to detect differences in 
preferences based on observed characteristics they are limited in the number of subgroups that 
can be evaluated due to sample size issues. Segmentation techniques using finite mixture 
models
2,3
 might present more advanced statistical models to detect subgroup heterogeneity. 
However, the advantage of stratification models is that they are familiar to a wider audience and 
might therefore be more easily disseminated. In addition, if preference differences are based on 
an observed characteristic this knowledge can inform clinical practice and/or benefit risk 
assessment. 
A fourth limitation was that our sample was more highly educated than the national population 
between age 45-64.
4
 In addition our participants were more likely to take medication than a 2011 
national sample (93% v. 81% respectively)
5
 and were living with diabetes longer (12.6 years v. 
11.4 years).
6
 This reduces representativeness of our sample and might affect the generalizability 




Both the Prescription Drug User Fee Act (PDUFA) and the 21
st
 Century Cures Act call for 
continued efforts by FDA to incorporate the patient experience in drug development. To reduce 
regulators’ burden, the Paper Work Reduction Act requirements have been waived for studies 
conducted by FDA to receive patient input (21
st
 Century Cures). In addition, FDA has been 
tasked with providing guidance on how patient experience data might be collected and 
incorporated into benefit-risk assessment.  
The Center for Drug Evaluation and Research (CDER) and the Center for Devices and 
Radiological Health (CDRH) are collaborating on exploring strategies to incorporate patient 
perspectives in regulatory decision making. CDER is working on integrating qualitative data from 
a list of therapeutic areas into existing evidence-based review processes through the patient 
focused drug development program. This initiative consists of public workshops with disease 
communities to gather information about the experience of living with a particular condition. 
To properly account for patient preferences, investigators must have reliable and accurate 
methods, tools, and approaches. To that extend, FDA is now working on developing an approach 
to bridge from patient-focused drug development meetings to systematic tools to collect 
meaningful patient input that can be incorporated into regulatory review. Stated-preference 
studies have been used before to present information on the patient experience and treatment 
preferences at public meetings at FDA
7
 and could continue to be a valuable tool.  
FDA is committed to improving review transparency, including how they conduct their benefit-
risk assessments and how they arrive at approval decisions.
8
 If patient preference information is 
to be included in patient-centered benefit risk assessment, these studies need to meet the same 
level of transparency as clinical evidence studies.  
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In addition, CDRH now requires that patient-preference data satisfies standards of valid scientific 
evidence. It has released guidance on voluntary submission of patient preference information.
9
 In 
this guidance they specifically mention the use of stated-preference methods to collect patient-
preference information. This strategy could facilitate integrating patient perspectives directly with 
clinical data on benefits and harms.
10
 
The guidance disseminated by CDRH recognizes that these various approaches exist and 
therefore does not make recommendations regarding specific methods that should be employed to 
measure patient preference information. Good research practices can reasonably include a variety 
of processes through all stages of a stated-preference study. There may be study-specific factors 
that determine good research practices, such as the homogeneity of the population under study, 
study resources, and funder requirements.  For example, while conducting qualitative work 
during instrument development constitutes good research practices the precise method can vary 
from interviews or focus groups, to informal consultation with patients and other stakeholders. 
11
  
There are always trade-offs between efficiency, comprehensiveness, and resources required to 
conduct a study. While investigator discretion is required based on the study objective and 
resources available, FDA guidance can be highly influential in determining minimum 
requirements for studies used in benefit-risk assessment. To that extend the CDRH guidance 
includes 11 qualities that should be considered when conducting a patient preference study.
9
 
As quantitative patient preference information is intended to represent the patients’ voice in 
benefit-risk assessment, CDRH first study quality, patient centeredness, might be the most 
important. While FDA also recognizes relevance as a desirable study quality, the guidance 
focuses on clinical relevance, not relevance to the patient experience. As a recent public meeting 
at FDA around clinical endpoints in diabetes indicates,
12
 endpoints that are recognized as 
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clinically relevant might not be patient-relevant. A balance between these two interests needs to 
be reached. 
Many of the qualities FDA describe on ensuring comprehension by study participants so the 
preference study can be successfully. Study comprehension might be aided by focusing on two 
other study qualities: the need to minimize cognitive bias, and the need for proper communication 
of benefit, harm, risk and uncertainty. To meet these three qualities, cognitive pretest interviews 
should be employed.  
FDA urges researcher to follow proper study conduct and established good research practices. 
These qualities are not clear-cut as gaps regarding good-research practices exist. In addition, 
while FDA asks to ensure that preference results meet logical soundness, qualitative work has 
shown that preference results that seem to violate rationality on the surface are logical from the 
patient’s perspective.
13,14
 Therefore, ensuring logical soundness might not be as straightforward 
as expected.   
Representativeness and generalizability of results is a quality that is advocated by FDA and is 
generally considered a positive, if not essential, aspect of high quality studies. Unfortunately, 
representativeness of the sample might come at a high financial and time cost. Considering that 
previously the patient’s voice was represented solely through anecdotes of select patient 
representatives, almost any quantitative sampling strategy presents an improvement. If much 
emphasis gets placed on ensuring generalizability of results, financial resources associated with 
conducting a stated-preference study might be prohibitive to patient-advocacy groups interested 
in conducting patient preference studies for consideration in benefit-risk assessment.
15
 This would 
severely limit the opportunity of patient advocacy groups to make their patients’ voices heard. 
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Ensuring robustness of the statistical analyses is important to evaluate preference results. The 
uncertainty in the results might be reduced by incorporating techniques that capture heterogeneity 
of patients’ preferences. While not always emphasized in traditional research, results should be 
presented and explained so that patients and others without statistical expertise can interpret the 
data. For that reason, complex statistical approaches (such as latent class analysis) could be 
supplemented by less complex approaches (such as stratification) to ensure that a lay audience 
can understand the results. 
In future guidance, FDA will need to consider which study qualities to prioritize. Preference 
studies that do not focus on representing the patient experience will ultimately fail at 
incorporating the patients’ voice into benefit risk assessments. By setting standards and providing 
further guidance, FDA can ensure that the collection of patient preference information is not just 
a token activity but will truly advance the incorporation of the patient experience into regulatory 
decision making.  
Further considerations  
While the place of patient preferences in healthcare decision making is being recognized, there is 
still little systematic or evidence-based application of patient preferences in healthcare decision 
making.
16
 To ensure the use of preference information in healthcare decision making, quality of 
preference results needs to be able to be evaluated. Standards to evaluate the quality of a stated-
preference study, through tests for data quality and through establishing standard procedures or 
reporting templates, can ensure the transparency, reproducibility, and validity of stated-preference 
studies. 
Future studies need to consider what these desirable properties of stated-preference studies are 
and how these properties compare to regular study and survey design. Given the patient-centered 
nature of preference research, research standards might focus around patient engagement and 
 152 
relevance and less around ensuring theoretical validity. Standards that would only focus on 
theoretical validity without representing patients’ voices would not be appropriate for 
incorporating the patient experience into healthcare decision making. 
In this dissertation, we have applied good research practices in stated-preference methods by 
measuring treatment preferences of people with type 2 diabetes. The applications of our approach 
will help other researchers conduct high quality stated-preference research. Ultimately high 
quality patient preference information can be used in the benefit-risk assessment of medications 
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